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i 
SUMMARY 
 
 
Multiple system atrophy (MSA) is a neurodegenerative syndrome characterized by 
(oligodendro)glial cytoplasmic inclusions (GCIs) composed of -synuclein.  I have 
developed cell culture models of MSA based on overexpression of human -synuclein in 
primary mouse oligodendrocytes.  In oligodendrocytes derived from (PLP)--synuclein 
transgenic mice, elevation of -synuclein levels by proteasome inhibition induced GCI 
formation and enhanced apoptosis.  The same effects were observed in wild-type 
oligodendrocytes transduced with a lentiviral vector encoding -synuclein.  In contrast, 
lenti--synuclein failed to yield inclusions, and even prevented aggregation and 
cytotoxicity of -synuclein.  Selective caspase inhibitors blocking the intrinsic 
(mitochondrial) apoptosis pathway and the extrinsic pathway reduced SYN-mediated 
oligodendrocyte cell death.  -synuclein overexpressing oligodendrocytes strongly 
expressed the pro-apoptotic Fas receptor and were specifically sensitized to Fas-mediated 
apoptosis.  In MSA brain, Fas was expressed on oligodendrocytes with GCIs.  Thus, 
induction of -synuclein leads to GCI formation and may contribute to oligodendrocyte 
dysfunction and cell death in MSA. 
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Chapter 1:  GENERAL INTRODUCTION  
 
1 STRUCTURE AND PHYSIOLOGICAL FUNCTIONS OF -
SYNUCLEIN  
1.1 The synuclein protein family 
a α-synuclein   
 
In 1988, a novel protein was isolated from the electric lobe of the Pacific ray, Torpedo 
californica, and from rat brain (Maroteaux et al., 1988).  Due to its distribution on portions 
of the nuclear membrane and its presence in high concentrations in presynaptic nerve 
terminals, this protein was named α-syn (synapse) -nuclein (nucleus); however, 
localization of mammalian synucleins to the nucleus was not confirmed by subsequent 
studies.   
Human α-synuclein is a 140 amino acid protein that is ubiquitously expressed at high 
levels in all regions of the brain where it is estimated to account for up to 0.1 % of total 
brain proteins (Clayton and George, 1999; George, 2002).  α-synuclein is present most 
abundantly in presynaptic terminals (George et al., 1995; Iwai et al., 1995) from neurons of 
various regions of the central nervous system (CNS) including the neocortex, 
hippocampus, dentate gyrus, olfactory bulb, thalamus and cerebellum, and also in the 
amygdala and nucleus accumbens (George et al., 1995; Iwai et al., 1995; Jakes et al., 1994; 
Wersinger et al., 2004).  α-synuclein is also detected in perikarya within several brainstem 
structures, including raphe, hypoglossal, and arcuate nuclei (Giasson et al., 2001), in 
olfactory receptor neurons and basal cells of the olfactory epithelium (Duda et al., 1999).   
Although biochemical analysis revealed that α-synuclein is predominantly localized to the 
cytoplasm of presynaptic terminals (Hurtig et al., 2000; Iwai et al., 1995; Jakes et al., 1994; 
Masliah et al., 1996; Petersen et al., 1999), a small fraction of α-synuclein may be 
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associated with vesicular membranes (George et al., 1995; Irizarry et al., 1996; Jensen et 
al., 1998).  α-synuclein is enriched in synaptosomal preparations (but is not found in highly 
purified synaptic vesicle fractions) (George et al., 1995; Irizarry et al., 1996; Kahle et al., 
2002b).  Immunogold electron microscopy showed that α-synuclein is localized to the 
inner face of plasma membranes in close proximity, but loosely associated with, synaptic 
vesicles at axonal termini (Clayton and George, 1998; Iwai et al., 1995; Jenco et al., 1998a; 
Maroteaux et al., 1988).  Thus α-synuclein exists in both cytoplasmic and membrane bound 
forms, most likely in a dynamic equilibrium (Kahle et al., 2000; Nuscher et al., 2004).  
b -synuclein 
 
The second member of the synuclein protein family, initially named phosphoneuroprotein-
14 (Nakajo et al., 1993), was identified in bovine brain.  Because of its high homology 
with α-synuclein at the amino acid sequence level (62%), this protein was named -
synuclein (Jakes et al., 1994).  -synuclein, the most conserved of the synuclein proteins, is 
134 amino acids long and contains five repeats of the EKTKEGV consensus sequence 
(Figure 1). 
Like α-synuclein, -synuclein is predominantly expressed in neuronal axon termini of CNS 
neurons (Jakes et al., 1994; Nakajo et al., 1990; Nakajo et al., 1994) but its distribution 
throughout the brain is more even than that of α-synuclein (Abeliovich et al., 2000; Nakajo 
et al., 1994).  Similarities in sequence and predominant localization in presynaptic 
terminals may suggest that α- and -synuclein share similar functions.   
 
c -synuclein   
 
GENERAL INTRODUCTION 
 
 3 
Another synuclein homologue, originally called breast cancer-specific gene-1 protein, was 
identified in 1997 in metastatic brain cancer tissue (Ji et al., 1997).  Due to its significant 
sequence homology with α-synuclein (55%), this protein was named -synuclein (Lavedan 
et al., 1998b) and is also refered to as persyn (Ninkina et al., 1998) or synoretin 
(Surguchov et al., 1999).   
-synuclein is 127 amino acids long and like α-synuclein, it contains six repeats of the 
EKTKEGV consensus sequence.  -synuclein is expressed in CNS as well as in the spinal 
cord, but it is most abundant in the peripheral nervous system including neurons of the 
dorsal root ganglia and trigeminal ganglia (Buchman et al., 1998; Lavedan et al., 1998a). 
Whereas α-synuclein and -synuclein are concentrated in synaptic vesicles, with little 
staining in cell bodies and dendrites, -synuclein is distributed throughout the neuronal 
cytosol (Buchman et al., 1998). 
 
Figure 1:  Amino acid sequence alignment of the human synuclein proteins.  The imperfect 
EKTKEGV repeats are identified.  The black background highlights amino acid residues conserved 
between α- and -synucleins (Jakes et al., 1994), and -synuclein (Ji et al., 1997).  The very high 
conservation between species for EKTKEGV consensus sequence suggests that the repeats have arisen 
from the duplication of a single domain within an ancestral synuclein gene. 
1.2 Structural properties of α-synuclein 
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α-Synuclein consists of three major regions (figure 2):  
(1) The highly conserved N-terminal region contains 60 amino acid residues and four 
repeats, with each repeat containing an imperfectly conserved KTKEGV motif (Clayton 
and George, 1998; George, 2002).  These repeats form amphipathic α-helices similar to 
apolipoprotein class A2 molecules through which membrane binding becomes stabilized 
(Davidson et al., 1998; Eliezer et al., 2001; Perrin et al., 2000).   
(2) Residues 61–95 form the hydrophobic and amyloidogenic central region, referred to as 
the non-amyloid component (NAC) of the amyloid precursor protein (see part 2.3), which 
includes two additional EKTKEGV repeats.  This domain is the building block of α-
synuclein aggregation (Giasson et al., 2001; Kahle et al., 2002a), with critical residues for 
the fibrillization of the protein being residues 66 to 74 (Du et al., 2003).  -synuclein lacks 
11 amino
 acids in the region corresponding to NAC (Figure 1).  β-synuclein is a non-
amyloidogenic homolog of α-synuclein and may act as a physiological inhibitor of α-
synuclein aggregation (see part 2.1; (Hashimoto et al., 2001).   
(3) The C-terminal acidic tail (residues 95-140) is less well conserved and rich in 
glutamate and aspartate residues.  This domain remains free and unfolded upon membrane 
binding, potentially providing a site for interactions with binding partners (Eliezer et al., 
2001) (see part 2.1).  Post-translational modifications such as phosphorylation can occur at 
serine 129 (Fujiwara et al., 2002; Okochi et al., 2000) and/or Tyr125 (Ellis et al., 2000). 
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Figure 2:  Schematic diagram of α-synuclein structure 
 
The structure of α-synuclein allows the molecule to exhibit different conformations 
depending on its interacting environment (Uversky, 2003).  This protein is natively 
unfolded in solution (Weinreb et al., 1996), adopts an α-helical conformation upon binding 
to lipid vesicles (Davidson et al., 1998), or forms β-pleated sheets in its aggregated form, 
suggesting highly dynamic structural changes depending upon the local cellular milieu.  
Nuclear magnetic resonance and electron paramagnetic resonance spectroscopy analysis 
indicates that binding of α-synuclein to lipids induces a reorganization of the repeats into 3 
complete helical turns (Bussell and Eliezer, 2003; Jao et al., 2004).   
1.3 Functions of α-synuclein 
 
As mentioned above, α-synuclein exists physiologically in both soluble and membrane-
bound states, in natively unfolded and α-helical conformation, respectively.  The 
physiological function of α-synuclein appears to require its translocation between these 
subcellular compartments and interconversion between the 2 conformations.  However, the 
general functions of α-synuclein under physiological conditions remain unclear and many 
roles for this protein have been proposed. 
a α-Synuclein effects on synapse organization and on synaptic vesicle 
maintenance 
 
P 
P 
-C 
N-terminal repeat region 
(lipid binding domain) 
N- 
Flexible  
acidic tail 
1 2 3 4 5 6 (-) 
NAC  
domain 
1 140 61 95 
Ser129 
Tyr125 
P 
P 
(-) (-) (-) (-) 
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Much research has been carried out in humans, mice, and chickens to study the role of α-
synuclein in neuronal development/synaptic plasticity (Eells, 2003; Sidhu et al., 2004b) 
and synaptic vesicle formation (Lotharius et al., 2002; Lotharius and Brundin, 2002).  α-
synuclein is initially present in the perikarya of mature neurons and is translocated to axon 
terminals between 15 and 18 weeks of gestation (Galvin et al., 2001; Murphy et al., 2000).  
Therefore, α-synuclein does not appear to play a role in initial synapse formation since it is 
expressed later in development and localizes to synapses after they are formed (Murphy et 
al., 2000; Withers et al., 1997).  Abeliovich et al. developed mice homozygously deleted 
for α-synuclein by targeted gene disruption.  These mice were viable and fertile; they 
exhibited no morphological deficits and possessed a normal complement of neuronal cell 
bodies, fibers, and synapses (Abeliovich et al., 2000; Cabin et al., 2002), providing further 
evidence that α-synuclein is not necessary for synaptic development.  However, these mice 
exhibited significant impairments in synaptic response to tetanic stimulation, suggesting 
that α-synuclein may regulate synaptic vesicle mobilization at nerve terminals (Abeliovich 
et al., 2000).   
b α-Synuclein effects on synaptic vesicle recruitment 
 
Converging observations suggest that a primary function for
 α-synuclein may be the 
physiological maintenance of synaptic homeostasis and plasticity (George et al., 1995; Iwai 
et al., 1995; Jakes et al., 1994; Sidhu et al., 2004b).  α-synuclein has been suggested to 
regulate axonal transport of synaptic vesicles (Jensen and Gai, 2001; Sidhu et al., 2004b), 
by interacting with several proteins that either bind to, or are part of the cytoskeleton, such 
as tubulin, tau, microtubule-associated proteins (Payton et al., 2001; Sidhu et al., 2004b). 
α-synuclein effect on synaptic vesicle cycling may be partly mediated through the ability 
of its N-terminal repeat region (residues 7-87), to physically interact with, and inhibit, the 
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activity of phospholipase D2 (PLD2) (Ahn et al., 2002; Jenco et al., 1998a), an enzyme 
localized primarily along the plasma membrane (Colley et al., 1997).  Activation of PLD2 
in the plasma and endosomal membranes, regulates the recycling of synaptic vesicles at or 
near the plasma membrane or endosomal compartments in response to external stimuli, and 
is instrumental in vesicle formation, through production of phosphatidic acid which 
recruits adaptor molecules, which, in turn, trigger the building of vesicles from donor 
membranes (Lotharius et al., 2002; Lotharius and Brundin, 2002). The regulatory effect of 
α-synuclein on synaptic vesicles recycling may be tightly regulated by various 
serine/threonine or tyrosine protein kinases (Lotharius and Brundin, 2002; Sidhu et al., 
2004b).  Hence, by inhibiting PLD2, α-synuclein may play a role in the control of synaptic 
vesicle cycling (Jenco et al., 1998b).  Phosphorylation of membrane-bound α-synuclein by 
G-protein coupled receptor kinases, lowers its ability to inhibit PLD2 activity (Lotharius 
and Brundin, 2002).  Binding of phosphorylated -synuclein to phospholipids is reduced 
(Sidhu et al., 2004b) and as a consequence monomeric α-synuclein is released into the 
cytoplasm (Leng et al., 2001; Pronin et al., 2000).  Thus, through reduction of its tonic 
inhibition of PLD2, phosphorylated α-synuclein might promote vesicle recycling during 
periods of high neuronal activity and favor synaptic plasticity, whereas non-phosphorylated 
α-synuclein may suppress synaptic vesicle formation during periods of low neuronal 
activity (Sidhu et al., 2004b).   
The modulation of vesicle recycling by α-synuclein may also be partly mediated through 
its putative ability to transfer fatty acids to sites of synaptic vesicle formation (i.e. early 
endosomes) and/or regulate the turnover or local organization of polyunsaturated fatty acid 
acyl groups implicated in clathrin-mediated endocytosis and, therefore, in vesicles 
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recycling (Lotharius et al., 2002; Lotharius and Brundin, 2002).  These fatty acid-binding 
protein properties of α-synuclein rely on two observations:  
 its N-terminal lipid (and vesicles) binding domain (residues 7-87; figure 2) bears 
significant homology with the lipid-binding class A apolipoproteins A2 and C 
(George, 2002; Goedert, 2001; Maries et al., 2003), proteins implicated in lipid 
transport (Sharon et al., 2001). 
 short amino acyl stretches in α-synuclein N- and C-termini share more than 55 to 
67% identity with a cytosolic fatty acid-binding motif of fatty acid-binding proteins 
(Sharon et al., 2001).   
c α-Synuclein effects on neurotransmission 
 
Many studies suggest the important role of α-synuclein in the regulation of 
neurotransmission and in the physiological maintenance of dopamine (DA) homeostasis in 
dopaminergic neurons of the substantia nigra pars compacta (Abeliovich et al., 2000; 
Lotharius et al., 2002; Lotharius and Brundin, 2002; Perez et al., 2002; Sidhu et al., 
2004b).   
Although α-synuclein knock-out mice display normal brain development and neuronal 
architecture, some small functional abnormalities in the dopaminergic system, reflected by 
a reduction in striatal DA and an attenuation of DA-dependent locomotor response to 
amphetamine, have been reported (Abeliovich et al., 2000).  DA release and reuptake was 
studied in striatal brain slices of these mice.  After stimulation of α-synuclein knock-out 
mouse striatal brain slices, nigrostriatal terminals displayed a standard pattern of DA 
release and reuptake in response to simple electrical stimulation.  However, they exhibited 
an increased DA release with paired electrical stimuli, as compared to wild-type mouse 
brain slices, suggesting that α-synuclein is a negative regulator of DA neurotransmission 
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(Abeliovich et al., 2000).  In a second study, ultrastructural examination of synapses of α-
synuclein knock-out mice also showed a reduction in the reserve-resting pool of synaptic 
vesicles in the hippocampus (Cabin et al., 2002).  These data were consistent with previous 
in vitro data (Murphy et al., 2000).  After lowering the amount of α-synuclein in cultured 
rat hippocampal neurons using antisense oligonucleotides, Murphy et al. (2000) detected a 
decrease in the number of resting-reserve synaptic vesicles, suggesting that α-synuclein 
may be required for the genesis and/or maintenance of a subset of presynaptic vesicles, 
those in the „reserve‟ or „resting‟ pools (Cabin et al., 2002).   
A more specific link to DA neurotransmission was established by the findings that -
synuclein binds to tyrosine hydroxylase, the rate-limiting enzyme for DA synthesis (Perez 
et al., 2002) and to dopamine transporter (DAT) (Lee et al., 2002; Wersinger and Sidhu, 
2005), thereby controlling the extravesicular cytoplasmic levels of DA (Sidhu et al., 
2004b).  Disruption of this function of α-synuclein can result in abnormal intracellular and 
extracellular DA content, which upon autoxidation and enzymatic metabolization can 
generate reactive oxygen species, ultimately leading to cell death.  α-Synuclein interacts 
directly with the DAT (Lee et al., 2001a) through its NAC domain (Wersinger and Sidhu, 
2003).  It was recently demonstrated that in the presence of α-synuclein, DAT is 
dynamically trafficked away from the plasma membrane into the cytoplasm (Wersinger et 
al., 2003; Wersinger and Sidhu, 2003).  These findings suggest that α-synuclein may act to 
tether the DAT to a cytoplasmic compartment, thereby keeping it away from the cell 
surface.   
Studies linking 1-methyl-4-phenylpyridinium ion (MPP
+
), a neurotoxin that inhibits 
mitochondrial complex I, and α-synuclein effects further implicate a role of α-synuclein in 
the regulation of DAT.  MPP
+
, whose intracellular transport within neurons occurs 
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specifically only through the DAT in an energy-dependent manner, reversed the inhibitory 
effects of α-synuclein on DAT (Wersinger et al., 2003).  The presence of α-synuclein 
enhances the vulnerability of cells to MPP
+ 
exposure (Kanda et al., 2000), whereas α-
synuclein null-mice are essentially resistant to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced degeneration of dopaminergic neurons (Dauer et al., 
2002).  Schluter et al. generated α-synuclein-deficient mice by homologous recombination.  
Upon acute MPTP challenge, α-synuclein knockout mice were partly protected from 
chronic depletion of nigrostriatal DA when compared with littermates of the same genetic 
background (Schluter et al., 2003). 
d α-Synuclein and neuroprotection 
 
Several studies indicate that α-synuclein may have a neuroprotective effect by modulating 
the expression levels or activity of anti-apoptotic molecules and decreasing the 
expression/activity of pro-apoptotic molecules after exposure to certain neurotoxins, 
oxidative stress, and glutamate-induced excitotoxicity (da Costa et al., 2000; da Costa et 
al., 2003; Hashimoto et al., 2002; Lee et al., 2001b).  The anti-apoptotic effect of α-
synuclein seems to be mediated by a stimulation of the PI3/Akt signaling pathway (Seo et 
al., 2002), followed by an increase in the expression levels of the anti-apoptotic protein 
Bcl-2 (Seo et al., 2002), and an inhibition of the activity of proapoptotic proteins (da Costa 
et al., 2000; Hashimoto et al., 2002; Lee et al., 2001b).  Although it is conceivable that 
neuroprotection may be a putative physiological function for this protein that may be lost 
under pathological conditions (Sidhu et al., 2004a), targeted disruption of α-synuclein gene 
did not interfere with programmed cell death (Abeliovich et al., 2000).  Further, -
synuclein knock-out mice display striking resistance to MPTP induced degeneration of 
dopaminergic neurons (Dauer et al., 2002).  Contrary to predictions from in vitro data, this 
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resistance was not due to abnormalities of the DAT, which appeared to function normally 
in the null mice.  
e α-Synuclein: a molecular chaperone protein  
 
Conformational analysis of human α-synuclein has demonstrated that this protein is 
natively unfolded, leading to the speculation that it could be involved in protein–protein 
interactions (Weinreb et al., 1996).  Its variable carboxyl terminal acidic tail (residues 95-
140) suggests a chaperone-like activity for α-synuclein (Uversky, 2003).  Furthermore, this 
protein binds to and shares 40% sequence homology with the cytoplasmic chaperone 14-3-
3 (Ostrerova et al., 1999), lending more support to the hypothesis that α-synuclein may 
also function as a molecular chaperone, thus displaying pleiotropic effects in cells (Souza 
et al., 2000).  It was shown in vitro that recombinant alpha-synuclein has a chaperone-like
 
function against thermal and chemical stress (Kim et al., 2000). 
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2 ROLE OF -SYNUCLEIN IN NEURODEGENERATIVE 
DISEASES 
 
α-synuclein is the major building block of pathological inclusions that characterize many 
neurodegenerative disorders, including Parkinson‟s disease (PD), dementia with Lewy 
bodies (DLB), neurodegeneration with brain iron accumulation type 1 (NBIA-1) and 
multiple system atrophy (MSA), collectively termed α-synucleinopathies (Trojanowski and 
Lee, 2002).  Pathological aggregates specifically contain α-synuclein but not -and -
synucleins.  The factors leading to aggregation of α-synuclein are of critical importance as 
potential mechanisms of pathogenesis.  
 
2.1 α-Synuclein aggregation and toxicity  
 
α-synuclein was demonstrated to self-aggregate into protofibrils, small α-synuclein 
oligomers which precede the development of larger fibrillary aggregates, and amyloid like 
fibrillar conformations (Conway et al., 1998; Conway et al., 2000a; Conway et al., 2000b; 
Giasson et al., 1999; Paik et al., 1998; Serpell et al., 2000).  Polymerization is associated 
with a concomitant change in secondary structure from random coil to anti-parallel -sheet 
structure (Narhi et al., 1999) consistent with the thioflavin S reactivity of these fibrils 
(Hashimoto et al., 1998; Narhi et al., 1999).  -synuclein is not only devoid of pathological 
aggregation capacity, but even suppresses α-synuclein aggregation (Park and Lansbury, 
2003).  Overexpression of -synuclein in α-synuclein transgenic mice reduces the number 
of α-synuclein inclusions (Hashimoto et al., 2004).  In DLB patients (see part 2.3.b), 
increased α-synuclein expression combined with decreased -synuclein expression was 
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detected (Rockenstein et al., 2001).  Thus the balance between both synucleins in vivo 
might be an important factor regulating α-synuclein aggregation.  
The formation of α-synuclein fibrils is greatly accelerated in vitro above a critical 
concentration of purified recombinant α-synuclein (Conway et al., 2000a; Giasson et al., 
1999; Hashimoto et al., 1998; Serpell et al., 2000) and by increased expression levels of α-
synuclein in transgenic animals (Giasson et al., 2002; Lee and Lee, 2002; Neumann et al., 
2002).  However, since α-synuclein is ubiquitiously expressed in the brain it is unlikely 
that high expression levels of α-synuclein are the sole criteria to cause protofibril and/or α-
synuclein aggregation in synucleinopathies (see part 2.3 for definition).  In fact, many 
other factors can also influence the fibrillization of α-synuclein.  Catecholamines, 
including DA, can form covalent adducts with α-synuclein and thereby increase the 
number of α-synuclein protofibrils (Conway et al., 2001).  This might explain the 
vulnerability of dopaminergic neurons of the substantia nigra pars compacta in PD.   
The specific vulnerability of certain cell types to degenerate in α-synucleinopathies may be 
linked to additional factors such as the presence of metals which have also been implicated 
in α-synuclein aggregation.  It was shown that ferrous iron stimulates α-synuclein 
aggregation in different cell lines (Ostrerova-Golts et al., 2000), and the concomitant 
presence of hydrogen peroxide accelerates the formation of insoluble amyloid-like α-
synuclein aggregates by means of the Fenton reaction (Hashimoto et al., 1998).  Free 
radicals such as free iron or iron-centered radicals (Youdim, 2003) accelerate and stabilize 
the formation of α-synuclein protofibrils (Lee and Lee, 2002; Volles and Lansbury, 2003) 
by inhibiting the conversion of soluble protofibrils into insoluble fibrils (Conway et al., 
2001; Li et al., 2004).  This is particularly interesting regarding the high concentrations of 
iron in human substantia nigra pars compacta and in oligodendrocytes, which display α-
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synuclein aggregates and signs of degeneration in PD and MSA respectively (see part 2.3.a 
and 3.1). 
Post-translational modifications such as phosphorylation at Ser129 has been also shown to 
induce or accelerate α-synuclein aggregation, both in vivo and in vitro (Chen et al., 2005; 
Fujiwara et al., 2002; Smith et al., 2005).  Only 4% of α-synuclein is Ser129 
phosphorylated under steady state physiological conditions, contrasting with the massively 
disproportionate concentration of phosphorylated α-synuclein (90%) in proteinaceous 
inclusions characteristic of specific neurodegenerative diseases (respectively part 2.3 and 
3.1).  This findings suggest that extensive phosphorylation at Ser129 of α-synuclein in the 
brain is a highly pathological event.  However, these correlative studies did not answer the 
question whether Ser129-phosphorylation is a cause or rather a secondary effect of -
synuclein fibrillization in vivo.  
Furthermore, α-synuclein monomer containing a tissue transglutaminase crosslinked 
intramolecular bond was extracted from PD substantia nigra pars compacta (Andringa et 
al., 2004).  The presence of this abnormal internal bond may impair the ability of α-
synuclein to interconvert between its α-helical configuration when bound to membrane and 
its unstructured cytoplasmic form, a process that appears to be necessary for its normal 
function.  Concentration of this isoform increases with disease progression and might serve 
as a nucleation site that could initiate α-synuclein filament assembly. 
Converging evidence that α-synuclein can function as nucleation site and promote 
aggregation under certain conditions has led several groups to investigate the direct effects 
of α-synuclein on cell viability.  It is believed that the α-synuclein toxicity is associated 
with its oligomerization into soluble protofibrils.  Protofibrils have been shown to penetrate 
membranes and form pore-like channels through which contents of vesicle membranes can 
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leak (Figure 3), elevating intracellular levels of potential cytotoxins such as calcium and 
DA (Conway et al., 1998; Conway et al., 2000b; Conway et al., 2001; Lashuel et al., 
2002a; Rochet et al., 2000; Volles et al., 2001).  
 
Figure 3:  Putative model for pathological α-synuclein inclusion formation.  Disordered monomeric 
(green starburst) α-synuclein oligomerizes to form a heterogeneous population of -sheet rich 
protofibrils (red), which includes pore-like structures (electron micrograph, image-averaged, 10-12nm 
outer diameter, from (Lashuel et al., 2002b).  Insertion of the protofibril pore into a membrane, which is 
thought to account for protofibril permeabilizing activity, is shown schematically.  The protofibril 
population dissipates as amyloid fibrils (orange rods) are formed.  Eventually, the fibrils coalesce to 
form a unique cytosolic proteinaceous inclusion.  A Lewy body (see part 2.3) is shown in the tissue 
section at the far right. [Modified from (Volles and Lansbury, 2003)] 
 
Recently, it has been suggested that α-synuclein fibrils may in fact be neuroprotective as a 
cellular response to sequester the toxic protofibrils (Caughey and Lansbury, 2003) and α-
synuclein aggregates are formed as a compensatory attempt to sequester neurotoxic 
molecules (Tanaka et al., 2004). However, ultimately, the accumulation of a large volume 
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of non degradable protein aggregates would be predicted to crowd cellular machinery and 
impair cellular transport, thereby inducing cell death.   
In addition it is conceivable that formation of protofibrils and aggregation of α-synuclein 
during the pathological process of α-synucleinopathies reduces the bioavailability of the 
physiological form of α-synuclein and may dampen the “anti-apoptotic” and 
neuroprotective effects of physiological concentrations of α-synuclein. 
 
2.2 Possible role of proteasome inhibition on α-synuclein fibril formation 
 
Understanding of the normal cellular α-synuclein processing may give clues about 
potential reasons for α-synuclein aggregation and subsequent toxicity (Figure 4).  The 
ubiquitin proteasome system (UPS) is the primary pathway for degrading and clearing 
proteins that have been damaged or are no longer needed (Friguet et al., 2000). To enter 
this pathway, proteins are tagged with ubiquitin and then enter the large multiprotein 
proteasome complex, where they are broken into peptide fragments (Weissman, 2001).  
The UPS appears to be the major machinery responsible for degradation of α-synuclein, 
although direct catabolism by the proteasome 20S core (Tofaris et al., 2001) and autophagy 
(Cuervo et al., 2004; Webb et al., 2003) has been reported. Prior to the discovery that α-
synuclein was the dominant component of cytosolic proteinaceous inclusions found in 
many neurodegenerative diseases, ubiquitin antigenicity was the most reliable 
immunohistochemical marker of these inclusions (Gai et al., 2000; Lennox et al., 1989).  In 
addition to ubiquitin, which polymerizes on lysine residues of substrate proteins targeted 
for proteasomal catabolism, numerous enzymes and proteins related to the machinery of 
protein degradation have been identified in α-synuclein fibrous cytoplasmic inclusions, 
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including ubiquitin carboxyl-terminal hydrolase, a deubiquitinating enzyme, chymotrypsin 
A and proteasome subunits (Lowe et al., 1990).  The common appearance of components 
of the UPS machinery in α-synuclein aggregates suggests an unsuccessful attempt of 
degradation by the proteasome (Gai et al., 2000; Sharma et al., 2001).  Finally, studies have 
shown that PD patients have significantly reduced levels of proteasomal subunits in the 
substantia nigra pars compacta compared to age-matched healthy controls, and proteasomal 
function is impaired in idiopathic PD, further strengthening the links between UPS 
dysfunction and α-synuclein mismetabolism (McNaught et al., 2003; McNaught and 
Jenner, 2001; McNaught and Olanow, 2003). 
The level of protofibrils and aggregated forms of α-synuclein is likely to be modulated 
through the ubiquitin-proteasome pathway (Giasson and Lee, 2003), although a causal link 
between a decrease in proteasomal degradation and high amounts of α-synuclein 
aggregates has not yet been demonstrated in vivo.  The UPS is clearly saturable and excess 
aggregated protein leads to saturation of proteolysis systems, inducing feed-forward 
toxicity (Bence et al., 2001).  In fact, α-synuclein overexpression potentiates proteasome-
inhibitor mediated apoptosis (Tanaka et al., 2001) and its aggregation is enhanced by 
proteasome inhibition (Dawson and Dawson, 2003; Maries et al., 2003; Rideout et al., 
2001). 
α-synuclein could also inhibit the proteasome through a direct interaction.  It was shown 
that both monomeric and aggregated α-synuclein impair proteasome function (Stefanis et 
al., 2001) by binding directly to Tat-binding protein 1, a component of the 19S regulatory 
subunit of the proteasome (Ghee et al., 2000).  In the latter study, fibrillar α-synuclein had 
a much stronger inhibitory effect on the activity of the proteasome compared to the 
monomeric protein.  Taken together, these data imply that impairment of the ubiquitin 
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proteasome pathway may contribute to the pathophysiology of the neurodegenerative 
diseases defined by the mismetabolism of α-synuclein. 
 
 
 
 
 
 
Figure 4:  Postulated mechanisms of α-synuclein mediated toxicity.  The presence of cytosolic 
aggregates in -synucleinopathies is caused by a failure to properly dispose of α-synuclein.  α-synuclein 
protofibrils and intracellular protein aggregates have been shown to impair the proteasome potentially 
leading to enhanced accumulation.  Solid arrows indicate more established pathways, whereas dotted 
arrows indicate largely hypothetical mechanisms.  
Mutations (see part 2.3) 
Genomic multiplications  
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2.3 α-Synuclein aggregation in neuronal and glial diseases:  
α-synucleinopathies 
 
α-synuclein was first associated with a neurodegenerative disease when a fragment of -
synuclein corresponding to the NAC domain was detected in amyloid plaques in 
Alzheimer‟s disease patient brains (Iwai et al., 1996; Masliah et al., 1996; Takeda et al., 
1998a; Takeda et al., 1998b; Uéda et al., 1993).  This finding stimulated great interest 
among researchers in a potential role for this protein in Alzheimer‟s disease pathogenesis.  
However, further research failed to confirm that the NAC peptide is an integral component 
of senile plaques (Bayer et al., 1999; Culvenor et al., 1999).  
The discovery of α-synuclein in Lewy bodies in PD was followed quickly by its detection 
in cellular inclusions in several other neurodegenerative diseases including DLB (Baba et 
al., 1998; Spillantini et al., 1998a; Spillantini et al., 1998b), Hallervorden-Spatz syndrome, 
now known NBIA-1 (Arawaka et al., 1998; Saito et al., 2000), and MSA (Arawaka et al., 
1998; Arima et al., 1998b; Fujiwara et al., 2002; Gai et al., 1999; Saito et al., 2000; Tu et 
al., 1998; Wakabayashi et al., 1998).  Collectively, these neurodegenerative diseases that 
share α-synuclein pathology as a primary feature have come to be known as α-
synucleinopathies (Arawaka et al., 1998; Arima et al., 1998b; Fujiwara et al., 2002; Saito 
et al., 2000; Spillantini et al., 1998b; Tu et al., 1998; Wakabayashi et al., 1998)  
a Parkinson’s disease (PD) 
 
PD is a progressive neurodegenerative disease mainly affecting people from 65 years old 
and over
 
(Lim et al., 2002).  The primary pathology of PD is degeneration of the 
dopaminergic neurons of the substantia nigra pars compacta (Lang and Lozano, 1998a; 
Lang and Lozano, 1998b), leading to slowed movement, rigidity, rest tremor and gait 
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disturbances.  As the disease progresses, many patients develop cognitive dysfunction, 
which includes dementia
 
(Lim et al., 2002).  In contrast to other neurodegenerative 
disorders, there is relatively efficient symptomatic therapy for PD.  This mainly consists of 
DA replacement and surgical therapy (deep brain stimulation) that relieves most motor 
symptoms.  However, there is no proven therapy to prevent cell death or restore sick 
neurons to a normal state.  Dopaminergic neurons contain intracytoplasmic inclusions 
called Lewy bodies (LBs), which contain mainly -synuclein fibrils (10nm) (Spillantini 
et al., 1998b).  It is believed that α-synuclein, in patients with PD, undergoes a 
conformational change acquiring a predominantly -pleated sheet structure that facilitates 
polymerization of α-synuclein into amyloid fibrils (McNaught and Jenner, 2001).  
Dystrophic ubiquitin-positive neurites associated with PD pathology, known as Lewy 
neurites (LNs), are also α-synuclein positive (Braak et al., 1999; Spillantini et al., 1998b; 
Spillantini et al., 1997).  Immunoelectron microscopy studies of the ultrastructure of 
synuclein in LBs, have demonstrated that LBs consisted of α-synuclein forming radially 
filaments surrounding an unstructured α-synuclein core.  
Genetic studies have also highlighted the significant contribution of α-synuclein to the 
etiology of PD.  α-synuclein is a key genetic factor implicated in the pathogenesis of PD, 
as three substitution mutations in the gene encoding α-synuclein appear to be linked to 
hereditary PD (Krüger et al., 1998; Polymeropoulos et al., 1997; Zarranz et al., 2004).  
However, α-synuclein mutations causing disease have only been found in a small number 
of kindreds afflicted with familial PD and analysis of large number of patients with 
idiopathic PD (Chan et al., 1998) or other forms of inherited PD (Scott et al., 1999) failed 
to reveal mutations in α-synuclein gene.  The extreme rarity of α-synuclein mutations has 
therefore prompted investigators to examinate polymorphisms that may be linked to PD.  
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There is some evidence that a dinucleotide repeat polymorphism located at a significant 
distance upstream in the promoter region of the α-synuclein gene may be associated with 
increased risk of PD in Caucasians (Farrer et al., 2001; Kruger et al., 1999).  Similar 
observations concerning the variability of these repeats and allelic length as a risk for PD 
have been obtained by independent studies in an Asian population (Tan et al., 2000).  
Another study showed that this region may play a role in transcriptional regulation of α-
synuclein (Chiba-Falek and Nussbaum, 2001); thus α-synuclein may also play a role in PD 
pathogenesis through alterations in its transcriptional control. 
The recent identification of genomic triplication in α-synuclein gene suggests that 
overexpression of α-synuclein causes pathology in neurons.  Singleton and colleagues 
reported a triplication in a region of chromosome 4 that includes the α-synuclein locus and 
an estimated 17 other genes (Singleton et al., 2003).  Carriers of this triplication are 
predicted to have four functional copies of α-synuclein, arguing for an increased gene 
dosage as a cause for PD.  -synuclein locus duplication has also been reported to cause 
PD phenotype which, by contrast with -synuclein triplication families, closely resembles 
idiopathic PD with late age-of-onset, slow progression, and no prominent cognitive decline 
nor dementia (Ibanez et al., 2004).   
b Dementia with Lewy Bodies (DLB) 
 
DLB is considered to be the second most common form of neurodegenerative dementia 
after Alzheimer‟s disease (McKeith et al., 1996).  The age of onset is typically between the 
ages of 60 to 80 and males may be a greater risk.  The average length of duration is around 
6 years but is variable. The disease typically has a rapid, fluctuating progressive course.  
Scientists continue to search for a specific course of therapy for people with DLB.  
Treatment is symptomatic, often involving the use of medication to control the 
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parkinsonian and psychiatric symptoms. However, antiparkinsonian drugs that may help to 
reduce tremor and loss of muscle movement may actually worsen such symptoms as 
hallucinations and delusions.  Recently, several clinical trials using cholinesterase 
inhibitors have shown its efficacy in the symptomatic treatment of cognitive impairment in 
DLB patients (Aarsland et al., 2004; Werber and Rabey, 2001). 
Pathologically, DLB patient brains contain a large number of α-synuclein-positive LBs in 
neurons from the substantia nigra pars compacta like in PD and in the cerebral cortex, 
which is less common in PD (McKeith et al., 1996; Spillantini et al., 1997).  The number 
of LBs correlates with the severity of the dementia (Hurtig et al., 2000).  In addition to LB 
pathology, LNs are fairly abundant in the striatum of DLB brains, and these inclusions may 
contribute to the parkinsonian symptoms in DLB (Duda et al., 2002).  Because LBs and 
LNs in DLB are so similar to those found in PD and are also mostly composed of 
filamentous α-synuclein protein (Baba et al., 1998; Crowther et al., 2000; Spillantini et al., 
1998b; Spillantini et al., 1997), PD and DLB may share a common disease mechanism. 
c Neurodegeneration with Brain Iron Accumulation Type 1 (NBIA-1) 
 
NBIA-1 is a rare familial and sporadic neurodegenerative disorder (Jellinger, 1973).  
Disease onset is typically in late adolescence or early adulthood and the disease is 
unremitting in its progression (Jellinger, 1973).  The clinical symptoms include motor 
disabilities and rigidity, dementia and dystonia (Jellinger, 1973).  The pathology in NBIA-
1 consists of cerebral atrophy and lesioning in the globus pallidus; however, an intense 
accumulation of (Jankovic et al., 1985) in the substantia nigra pars compacta and globus 
pallidus is the prominent pathological hallmark of NBIA-1 (Dooling et al., 1974).  Axonal 
spheroids, LB-like lesions, and glial inclusions composed of insoluble, fibrillar α-synuclein 
are also present in brain of NBIA-1 patients (Galvin et al., 2000).  These inclusions are 
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found mostly throughout the cortex, subcortical regions, and brain stem (Arawaka et al., 
1998; Saito et al., 2000; Tu et al., 1998).  
 
3 MULTIPLE SYSTEM ATROPHY (MSA) 
3.1 Clinical characteristics and etiology of MSA  
 
In 1900, Dejerine and Thomas described 2 patients with a degenerative disorder leading to 
progressive cerebellar dysfunction, parkinsonism and prominent dysautonomia.  Upon 
postmortem examination of these brains, neurodegeneration was found in the inferior 
olives, pons and cerebellum, and the disease was termed olivopontocerebellar atrophy 
(OPCA).  In 1960, Shy and Drager described a neurological syndrome (Shy-Drager 
syndrome) of orthostatic hypotension in patients who also displayed parkinsonian features.  
Following this report, Van de Eecken, Adams, and van Bogaert reported more cases with 
the features of OPCA and Shy-Drager syndrome associated with striationigral degeneration 
and atrophy of the caudate nucleus and putamen; this disorder was named striatonigral 
degeneration (Adams et al., 1964).  In 1969, Graham and Oppenheimer noted that the 
clinical and pathologic findings of OPCA, striationigral degeneration, and Shy-Drager 
syndrome overlapped significantly although reflecting degeneration of separate neuronal 
subsystems.  They proposed the term multiple system atrophy (MSA) to describe patients 
with these disorders.  Since then, the discovery of the specific pathological lesions unique 
to MSA, known as glial cytoplasmic inclusions (GCIs; Figure 5), has confirmed that these 
diseases are clinical forms of the same syndrome (Papp et al., 1989a).  The lumping 
concept of MSA was detailed further in the clinical paper of Quinn which brought attention 
to the disease by introducing a first set of diagnosis criteria (Quinn, 1989). 
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The median age of onset is 55 years, but ranges from 33 to 76 years of age and affects 
more men than women (Wenning et al., 1995).  The symptoms of MSA progress faster 
than those of PD with an average patient survival of 6 to 7 years (Wenning et al., 2004).  
Approximately 0.31 % of people over 65 years old suffer of MSA (Trenkwalder et al., 
1995).  Assuming that there exist worldwide 600 million people older than 65, we 
extrapolate that 1.7 million may suffer from MSA.  However, the true prevalence of MSA 
has been underestimated, since many patients remain undiagnosed or misdiagnosed.  In 
fact, MSA is a difficult diagnosis (especially early in the clinical course) and is clinically 
commonly confounded with PD at the initial stage of illness.  Approximately 10% of 
patients diagnosed in life as having PD are found at autopsy to have MSA (Hughes et al., 
1992).  MSA is suggested when (1) disability progresses rapidly, (2) patients are poorly 
responsive to levodopa, (3) autonomic symptoms, ranging from impotence to urinary 
incontinence to orthostatic hypotension (drop in blood pressure when patient stands 
upright), are pronounced, (4) rigidity and bradykinesia are out of proportion to tremor and 
(5) severe dementia is absent.  Mild dementia is not uncommon, but severe dementia is 
atypical in MSA (Wenning et al., 1997b).   
Recently, two subtypes of MSA have been proposed (Gilman et al., 1999).  Parkinsonism 
predominant (MSA-P; 80% of MSA cases) and cerebellar ataxia predominant (MSA-C; 
20% of MSA cases) forms of the disease can be distinguished.  The different symptoms 
can be explained in part by the distinct brain regions affected: striatonigral degeneration in 
MSA-P and olivopontocerebellar atrophy in MSA-C.  However, the factors determining 
the regional specificity of neurodegeneration in MSA-P and MSA-C remain to be 
elucidated.   
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The cause of MSA remains unknown and no current therapy can reverse or halt 
progression of the disease.  A genetic component seems unlikely and screening studies for 
candidate genes revealed no risk factors (Bandmann et al., 1997; Nicholl et al., 1999).  
Autoimmune mechanisms and environmental toxins have been suggested to be involved in 
MSA pathogenesis (Hanna et al., 1999), but evidence for these etiologies is weak 
 
3.2 Neuropathological features of MSA 
 
Histopathological findings include moderate depigmentation of the substantia nigra pars 
compacta and locus ceruleus, and demonstrate neuronal and oligodendroglial cell loss as 
well as gliosis in striatum (mainly putamen), substantia nigra pars compacta, inferior 
olives, pons, cerebellum in addition to the intermediolateral cell columns and Onuf‟s 
nucleus in the spinal cord (Wenning et al., 1997a).  Microvacuolation within the involved 
neuronal systems has also been reported.  These findings are present to a lesser extent even 
in regions where atrophy is not noted.   
Initially, it was assumed that MSA was caused by gray matter damage.  Neuronal 
inclusions have been observed in both the cytoplasm and nucleus of neurons in patients 
with MSA (Papp and Lantos, 1992).  However, the discovery in 1989 by Papp and 
colleagues of GCIs being the hallmark lesion in MSA brains suggests that damage is 
primarily in the white matter (Figure 5) (Papp et al., 1989b).  GCIs are triangular shaped 
argyrophilic inclusions and, like LBs and LNs, are composed mostly of insoluble 
filamentous polymers of α-synuclein protein (Dickson et al., 1999; Duda et al., 2000; Duda 
et al., 2002; Gai et al., 2003; Gai et al., 1998; Tu et al., 1998).  Post-translational 
modifications, including phosphorylation at Ser129 (Fujiwara et al., 2002) and oxidative 
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nitration (Giasson et al., 2000) are prominently visualized in GCIs of MSA patients 
(Fujiwara et al., 2002).  α-synuclein mRNA has not been detected by in situ hybridization 
in oligodendrocytes from normal human adult brain (Solano et al., 2000b); however, it is 
transiently expressed in cultured oligodendrocytes and increased to peak levels at 2 or 3 
days (Richter-Landsberg et al., 2000).  It is not understood how in MSA α-synuclein gets 
into oligodendrocytes (by uptake from damaged fiber tracts or by de novo synthesis).  
The distribution of GCIs correlates with the subtypes of MSA, with putaminal lesions 
prevalent in patients with the MSA-P subtype and pontine lesions prevalent in patients with 
the MSA-C subtype (Arima et al., 1992; Duda et al., 2000; Papp et al., 1989b; Papp and 
Lantos, 1994b).  Furthermore there is significant correlation between the frequency of 
GCIs and the severity of neuronal cell loss and disease duration (Ozawa et al., 2002).  
Although GCIs resemble LBs, their shape, size, ultrastructure, imunocytochemical profile, 
and regional distribution are quite distinctive.  GCIs are composed of loosely aggregated 
20- to 30-nm tubular filaments intensely labeled with α-synuclein oligomers forming the 
central core fibrils of the glial inclusions (Gai et al., 2003).  Immunoelectron microscopy 
studies have demonstrated that α-synuclein filaments in GCIs are wider in diameter than 
those of LBs and LNs and are sometimes found in a twisted formation (Crowther et al., 
2000; Spillantini et al., 1998a).  The composition of GCIs is slightly different from LBs.  
The latter mainly contain α-synuclein along with some ubiquitin and neurofilament 
subunits; GCIs of MSA mainly contain α-synuclein in addition to αB-crystallin, ubiquitin, 
microtubule-associated proteins and α- and -tubulin, but lack neurofilament subunits 
(Arima et al., 1998b; Gai et al., 1999; Tamaoka et al., 1995).  GCIs frequently contain 
markers of cellular stress such as heat shock protein 70 (Namba et al., 1991), which is 
induced by various forms of cell stress.   
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Increasing evidence indicates that the formation of GCIs leads to cellular dysfunction.  It 
has been proposed that GCIs often entrap cytoplasmic organelles (eg, mitochondria, 
secretory vesicles) and disrupt normal protein and organelle trafficking within affected 
cells (Arima et al., 1998a; Tu et al., 1998).  These chronic alterations may lead to glial cell 
dysfunction and death and may impair trophic function between oligodendrocytes and 
axons, thereby causing neuronal damage. 
It was shown recently that extensive myelin abnormalities occur in the white matter of the 
involved regions in MSA.  Matsuo and colleagues reported extensive myelin degeneration 
in MSA brains (Matsuo et al., 1998) using antibodies
 
recognizing degenerating myelin but 
not normal appearing myelin (Matsuo et al., 1997).  The
 
presence of unusual myelin basic 
protein epitopes in MSA, in
 
both affected and unaffected brain regions, substantiates the
 
notion of widespread oligodendroglial dysfunction in MSA and
 
highlights white matter 
disease as an integral component.  The dysmyelination observed in MSA results from 
dysfunction of the oligodendrocytes, the cells which produce and maintain myelin in the 
CNS (see part 4.1).   
 
 
Figure 5:  -synuclein pathology in multiple system atrophy.  Immunostaining for -synuclein in 
paraffin sections (A, B, and C) in MSA. Note many GCI in white matter in basal ganglia (A and inset). 
In the pons (B and C) was a mixture of glial and neuronal inclusions. The neuronal inclusions were 
cytosolic and pleomorphic (C and inset). D: Double immunostaining of Vibratome sections with GFAP 
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(rhodamine filter, red) and -synuclein (fluorescein filter, green). Note the absence of colocalization of 
the two signals. Inset shows a GCI that is double labeled with -synuclein (fluorescein filter, green) and 
C4d (rhodamine filter, red) [from Dickson, 1999] 
 
3.3 Animal models of MSA 
 
The adverse consequences of α-synucleinopathy in MSA are not understood to date.  In 
order to shed light on the molecular pathology of α-synuclein in these diseases, several 
animal models have been generated (Fillon and Kahle, 2005; Stefanova et al., 2005c).  
Animal models of MSA are urgently required as test-bed for the evaluation of novel 
therapeutic interventions in the disorder.  Initial attemps to mimic MSA pathology in 
rodents relied on the destruction of brain regions that degenerate in human MSA-P 
(Wenning et al., 1999).  The nigral and striatal “double-lesion” rat model is based on 
sequential injection of 6-hydroxydopamine and quinolinic acid into the medial forebrain 
bundle and ipsilateral striatum, respectively (“double toxin-double lesion” approach).  
Intrastriatal injections of 3-nitropropionic acid and MPP
+
 in rodents result in secondary 
excitotoxic striatal lesions and subtotal neuronal degeneration of substantia nigra pars 
compacta, thus producing MSA-P like pathology by a simplified “single toxin-double 
lesion” approach.  However, such models do not show the neuropathological hallmarks of 
MSA.  Thus, chemical lesion models are of limited use for the investigation of MSA 
etiopathogenesis.  To gain further insight into the molecular mechanisms of MSA, 
transgenic mouse models are currently being developed. 
An early transgenic model of glial α-synucleinopathy relied on imperfect neuronal 
specificity of the including platelet-derived growth factor (PDGFpromoter.  Some 
transgenic α-synuclein expression was detected in glial cells of (PDGF)-α-synuclein 
mice, but α-synuclein fibrillization could not be demonstrated (Rockenstein et al., 2002).  
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In situ hybridization with transgene-specific probes directly demonstrated that the glial α-
synuclein protein was expressed from glial mRNA (Rockenstein et al., 2002).  Glial α-
synuclein was not observed in mice that expressed transgenic α-synuclein under the control 
of the highly neuron-specific Thy1 promoter (Kahle et al., 2000; Rockenstein et al., 2002; 
van der Putten et al., 2000).  These mouse model data do not support the hypothesis that 
the neuronal protein α-synuclein transmigrates from axons into oligodendrocytes in MSA 
patients. 
 
Specific, long-lasting expression of transgenic α-synuclein in oligodendrocytes throughout 
the brain was achieved with a myelin proteolipid protein (PLP) promoter (Kahle et al., 
2002b).  Unlike the disease-irrelevant control green fluorescent protein expressed under 
control of the same promoter, which evenly distributed throughout oligodendrocytes, α-
synuclein was asymmetrically clustered in the cytosol of oligodendrocytes.  The transgenic 
α-synuclein-positive profiles resembled the typical triangular and half moon-shaped GCIs 
of MSA patients (Lantos, 1998) at the light microscopic level.  Moreover, the pathological 
phosphorylation at Ser129 was recapitulated in (PLP)-α-synuclein mice.  Biochemical 
analysis confirmed the pathological insolubility of hyperphosphorylated, transgenic α-
synuclein in this mouse model.  However, in contrast to transgenic mice expressing high 
levels of α-synuclein in neurons (Neumann et al., 2002), oligodendroglial transgenic α-
synuclein did not fibrillize upon aging.  Possibly the employed oligodendrocyte-specific 
promoters do not lead to very high cytosolic α-synuclein  concentrations, or 
oligodendrocytes have a greater capacity to suppress α-synuclein  misfolding, either 
because of an abundance of small heat shock proteins (such as αB-crystallin) (Neri et al., 
1997) or because oligodendrocytes have a lower vulnerability toward pro-aggregative risk 
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factors than aged neurons.  One such risk factor may be exposure to environmental toxins.  
Transgenic (PLP)-SYN mice exposed to the neurotoxin 3-nitropropionic acid displayed 
exacerbated neuronal loss, astrogliosis and microglial activation (Stefanova et al., 2005b).  
The MSA-like pathology in this combined -synuclein / 3-nitropropionic acid mouse 
model caused severe motor impairment.   
Another risk factor might be concomitant tauopathy.  Tau protein, the microtubule-
associated protein
 
that is the major structural component of neurofibrillary tangles
 
in 
Alzheimer‟s disease and progressive supranuclear palsy, is like -synuclein a natively 
unfolded protein with little secondary
 
structure that forms pathologic filaments with 
unusual solubility
 
properties and protease resistance (Dickson et al., 1999).  When a 2‟,3‟-
cyclic nucleotide 3‟-phosphodiesterase (CNP) promoter was employed to express human 
α-synuclein in transgenic mouse oligodendrocytes, no particular pathology and phenotype 
were initially noted unless these animals were cross-bred with mice that express 
[P301L]tau in oligodendrocytes (Giasson et al., 2003a).  A subset of bigenic 
oligodendrocytes developed α-synuclein and tau fibrillar inclusions, as demonstrated by 
thioflavin S staining.  Such amyloid formation coincided with motor impairments.  It is 
tempting to speculate that in oligodendrocyte cytosol, α-synuclein and tau synergistically 
form individual fibrils, as was shown in vitro (Giasson et al., 2003a).  Tau pathology has 
been noted in some MSA individuals (Giasson et al., 2003b; Jaros and Burn, 2000; Piao et 
al., 2001a) but more systematic studies are warranted to distinguish the potentially 
synergistic co-fibrillization of tau and α-synuclein from, e.g., co-morbid MSA and 
progressive supranuclear palsy. 
Recently, Yazawa et al. (2005) followed the (CNP)-α-synuclein mice during aging and 
found a slowly progressive neurodegenerative condition associated with transgenic α-
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synuclein accumulation in oligodendrocytes in an age-dependent manner, leading to a 
primary loss of the glial cells and a secondary neuronal degeneration (Yazawa et al., 2005).  
The insoluble fibrillar α-synuclein inclusions show striking resemblance to GCIs.  The 
(CNP)-α-synuclein mouse has a normal life span; however, starting at three months of age, 
it begins to lose motor skills and paw strength.  The decline is associated with brain 
atrophy especially severe at 2 years compared to littermates.  In addition, neuronal and 
oligodendroglial cell loss is observed in the spinal cord.  Electon microscopy analysis 
reveals degenerating glial cells and autophagocytosis of myelin.  Neurons likewise show 
markers of injury and structural evidence of degeneration.  Interestingly, neurons in older 
(CNP)-α-synuclein mouse express higher levels of endogenous mouse α-synuclein in their 
axons, presumably in response to oligodendrocyte degeneration.   
Shults and colleagues tried to mimic MSA in a mouse by expressing human α-synuclein 
under the glial-specific MBP promoter (Shults et al., 2005). α-synuclein was highly 
expressed only in oligodendrocytes and formed detergent insoluble inclusions, which also 
contained phosphorylated -synuclein. α-synuclein aggregation in oligodendrocytes was 
accompanied by mitochondrial alterations, and the white matter tracts of these animals 
displayed intense astrogliosis, myelin pallor, and decreased neurofilament immunostaining.  
Furthermore, widespread signs of neurodegeneration including decreased dendritic density 
and loss of dopaminergic were also observed in these mice.  Starting at 2–4 months of age, 
the MBP--synuclein mice expressing high level of α-synuclein develop neurological 
alterations including tremors, ataxia, and seizure activity resulting in premature death at 6 
months.  Lower expressing mice show performance deficits at 6 month of age, presumably 
in response to oligodendrocyte degeneration.  In fact, their decline was associated with the 
highest concentration of a-synuclein immunoreactive inclusions in oligodendrocytes 
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(Shults et al., 2005). This model further suggests that accumulation of insoluble filamentous α-
synuclein in oligodendrocytes, leads to a primary loss of the glial cells and a secondary neuronal 
degeneration. 
The major breakthrough demonstrated with the (CNP)-α-synuclein and (MBP)-α-synuclein 
mice is the identification of a secondary neurodegeneration following oligodendrocyte α-
synucleinopathy.  This provides evidence that neuronal degeneration can occur as a direct 
consequence of oligodendrocytic GCI-like pathologies and suggests that aberrant 
expression of α-synuclein in oligodendrocytes could be sufficient to cause MSA.  
However, the mechanisms leading to oligodendrocyte loss and subsequent 
neurodegeneration in this model remain unknown.  Although it remains to be shown that 
oligodendrocytes induce the α-synuclein gene in human MSA patients, the (CNP)-α-
synuclein and (MBP)-α-synuclein mice may allow the study how oligodendroglial α-
synucleinopathy impairs myelination and axonal integrity.  Moreover, as models of glial-
driven neurodegeneration, they may be useful to test novel therapeutic approaches to treat 
MSA. 
The different transgenic animal models for MSA provide insights into various aspects of 
the oligodendroglial phenotype and its role as a target in the disease, and are quite 
persuasive in implicating α-synuclein in the pathogenesis of MSA.  These models indicate 
that a combination of genetic predisposition (ectopic α-synuclein expression in 
oligodendrocytes) and epigenetic factors (environmental toxins (Stefanova et al., 2005a), 
aging (Shults et al., 2005; Yazawa et al., 2005)) may contribute to MSA and represent 
useful tools to identify important pathways involved in α-synuclein toxicity which could be 
exploited for novel therapeutics in the treatment of MSA. 
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4 OLIGODENDROCYTES: POTENTIAL PRIMARY TARGETS IN 
MSA 
 
Neurodegeneration in MSA affects selected gray matter "systems"
 
whereas its hallmark 
inclusion-bearing cells are mostly found in white matter.
  
Implicating the oligodendrocyte 
as the primary target, therefore,
 
means providing a mechanism for region-specific 
oligodendrocyte
 
dysfunction or a mechanism whereby oligodendrocyte dysfunction
 
leads to 
pronounced destruction of selected vulnerable neuronal
 
populations.  To date there is little 
evidence that oligodendrocytes
 
may be subtyped according to the neuronal populations 
they subserve.
  
Older classifications of Mori and LeBlond (Mori and Leblond, 1970) and 
Stensaas and Stensaas (Stensaas and Stensaas, 1968) subtyped oligodendrocytes based on 
fine structural features
 
of the oligodendrocyte nucleus and processes and myelin sheaths,
 
respectively, providing indirect evidence for functional specialization,
 
but no conclusive 
evidence for tract specificity.  Additionally,
 
single oligodendrocytes have been shown to 
myelinate axons of
 
different anatomical tracts, casting some doubt on the possibility
 
that 
oligodendrocytes may be classified based on the functional
 
properties of corresponding 
axons (Sternberger et al., 1978).  In MSA, GCIs are reported
 
to involve so-called 
perivascular, perifascicular, and perineuronal oligodendrocytes
 
without further 
qualification as to subtype.  In essence, then,
 
GCIs involve all morphological types of 
oligodendrocytes with
 
varying frequency in specific anatomical regions (Lantos and Papp, 
1994; Papp and Lantos, 1994a).  It therefore
 
appears that oligodendroglial disturbance in 
MSA, whether or
 
not it occurs primarily, tends to be more generalized and would
 
likely 
have to occur in conjunction with intrinsic vulnerability
 
of selected neuronal populations, 
the nature of which remains
 
to be determined.  It is noteworthy in this regard that axonal 
damage is known
 
to occur in otherwise classical demyelinating conditions (Griffin et al., 
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1996; Trapp et al., 1998).  Furthermore, the critical trophic influences that are described
 
between oligodendrocytes and axons
 
(Kaplan et al., 1997) indicate that oligodendroglial
 
pathology would likely affect neuronal function. 
 
4.1 Oligodendrocyte functions in the CNS  
 
Glial cells represent the vast majority of cells in the CNS and outnumber neurons by 10 to 
1 and occupy half of the CNS space (Kettenmann 1995; Zhang 2001).  These cells help to 
construct the nervous system during embryonic development and maintain its functions.  
Rio Hortega introduced the term oligodendroglia to describe neuroglial cells with few 
processes in
 
material stained by metallic impregnation techniques (Baumann and Pham-
Dinh, 2001).  An oligodendrocyte extends
 
many processes, each of which contacts and 
repeatedly envelopes
 
a stretch of axon with subsequent condensation of this multispiral
 
membrane-forming myelin (Bunge et al., 1962; Bunge, 1968) (Figure 6).  The main and 
evident function of oligodendrocytes is the formation of a myelin sheath around most 
axons in the CNS (Figure 6).  Myelin functions as an insulator of the axons, and its 
structure facilitates rapid transmission of impulses.  Oligodendrocytes are able to myelinate 
up to 50 axonal segments, depending on the region of the CNS.  On the same axon,
 
adjacent myelin segments belong to different oligodendrocytes.   
In addition of being an insulating sheath that allows neurons to conduct electrical signals at 
high speed, myelin is involved in clustering of sodium
 
channels at the node of Ranvier 
(figure 6) during axogenesis, in axonal development and maintenance.  Finally, myelin 
regulates axonal growth
 
and regeneration (Baumann and Pham-Dinh, 2001).  Myelin 
contains proteins such as Nogo (Schwab, 2004) have been demonstrated to contribute to 
regenerative failure after CNS injury and to the limitation of lesion-induced plasticity. 
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Figure 6:  The oligodendrocyte and the mature myelin sheath.  An oligodendrocyte sends a glial 
process forming compact myelin spiraling around an axon.  Cytoplasm is trapped occasionally in the 
compact myelin.  In transverse sections, this cytoplasm is confined to a loop of plasma membrane, but 
along the internode length, it forms a ridge that is continuous with the glia cell body.  In the longitudinal 
plan, every myelin unit terminates in a separate loop near a node.  Within these loops, glial cytoplasm is 
also retained.  The tight wrapping of myelin prevents any ionic exchange or spread of electric current, 
therefore the action potential can only occur at the nodes of Ranvier which are devoid of myelin.  As 
shown above, when the action potential is present at one node, the influx of Na
+
 ions causes the 
displacement of K
+
 ions down the axon. Thus the action potential jumps from node to node.  Saltatory 
conduction increases conduction velocity and is very energy efficient, as only a small part of the axon is 
involved in the exchange of ions, much fewer ions need to be pumped back after the action potential has 
passed.  [Adapted from Bunge et al., 1968] 
 
Although the oligodendrocyte
 
is mainly a myelin-forming cell, there are also satellite
 
oligodendrocytes that may not be directly connected to
 
the myelin sheath.  Satellite 
oligodendrocytes are located in the grey matter, perineuronal
 
and regulate the 
microenvironment around neurons
 
(Ludwin, 1997).   
 
4.2 Origin of oligodendrocytes  
a Neuron-glia decision 
 
Na+ 
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Both intracellular factors as well as extracellular factors may exert influence on whether a 
neural cell becomes neuron or glia.  Accumulating evidence suggests that the Notch 
receptor promotes glial development at least partially via repressing the neurogenic basic 
helix-loop-helix protein (bHLH) transcription factors, promoters of neuronal fate 
(reviewed in (Kageyama and Nakanishi, 1997).  Notch signaling instructively commit CNS 
stem cells into the astroglial lineage, thus fulfilling the criterion for a molecular switch 
between neuronal and glial fate (Morrison et al., 2000; Tanigaki et al., 2001).  Neurons are 
generated before glial cells (Lu et al., 2000; Morrison, 2000; Yu et al., 1994; Zhou et al., 
2000).  Environmental factors present during early embryonic development favour 
neuronal development whereas those present at later stages favour glial development.  
Once a cell fate is chosen, other mechanisms presumably will step in to permanently lock 
the cell in this fate.  In addition, neural stem cells may contain an internal timer that counts 
time or cell division and that determines the sequential production of neuron and glia 
(Morrison et al., 2000).   
b Oligodendrocyte specification 
 
Oligodendrocyte precursors originate from neuroepithelial cells of the ventricular zones, at 
very early stages during embryonic
 
life.  As mentioned before, neurogenic bHLH factors 
control the neuron-glia decision.  The bHLH transcription factors Olig2 and Olig1 are 
absolutely required for oligodendrocyte fate determination (Balasubramaniyan et al., 2004; 
Lu and Sloan, 2002; Lu et al., 2000; Zhou and Anderson, 2002).  Olig1,2 double null 
mutants mice or neurosphere cultures fail to give rise to any oligodendrocytes (Lu et al., 
2002; Zhou and Anderson, 2002).  
Sonic Hedgehog (Shh), a morphogen that regulates the transcription of different target 
genes at different concentrations, is a potent inducer and obligatory for oligodendrocyte 
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generation in both rostral and caudal neural tube (Alberta et al., 2001; Nery et al., 2001; 
Orentas et al., 1999; Park et al., 2002; Tekki-Kessaris et al., 2001b).  Shh exerts its pro-
oligodendrocyte functions by inducing Olig genes (Lu et al., 2000; Nery et al., 2001).   
However Olig genes cannot substitute for Shh, as shown in zebrafish where forced Olig 
expression largely failed to rescue the oligodendrocyte failure in the absence of Shh 
signalling (Park et al., 2002).  Shh therefore must induce additional genes that cooperate 
with Olig to promote oligodendroglia fate. 
Members of the bone morphogenetic proteins, on the contrary, repress Olig gene 
transcription even in the presence of Shh and thereby act as potent inhibitors of 
oligodendrocyte fate (Gross et al., 1996; Mabie et al., 1999; Mehler et al., 2000; Mekki-
Dauriac et al., 2002). 
In summary, oligodendroglia fate specification requires the absence of general glial 
repressors such as neurogenic bHLH factors and the induction of Olig genes and their 
partners. 
c Spatial origin of oligodendrocytes 
 
Despite the wide distribution of mature oligodendrocytes throughout the CNS in adult 
vertebrate, it is now well established that oligodendrocyte precursors are generated in 
restricted regions of the CNS.  Mapping the birth place of glial cells has always been 
problematic due to the extensive migratory behavior of these cells.  Oligodendrocyte 
precursors found in the mid-
 
and forebrain originate from the ventral plate of the neural 
tube (Spassky et al., 1998).  Converging studies suggest that oligodendrocytes 
predominantly come from the ganglionic eminence area and later migrate throughout the 
brain (Olivier et al., 2001a; Tekki-Kessaris et al., 2001a; Woodruff et al., 2001).  
Oligodendrocytes may also derive from other brain loci, sites of oligodendrogliogenesis 
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(Olivier et al., 2001b; Spassky et al., 1998).  The initial restricted localization of 
oligodendrocyte precursors in the ventral plate of the neural tube appears not to be
 
limited 
to the mid-
 
and forebrain (Spassky et al., 1998).  Earlier this year Cai et al., and Vallstedt et 
al., provided compelling evidence for a second dorsal origin of oligodendrocyte precursors 
in the hindbrain and spinal cord while oligodendrocyte precursors have previously been 
localized to the ventral midline (Cai et al., 2005; Vallstedt et al., 2005).   
The subventricular zone is a germinal matrix of the forebrain that first appears during the 
later third of murine embryonic development (Doetsch et al., 1997).  It enlarges during the 
peak of gliogenesis, between 5 and 20 days in postnatal life,
 
and then shrinks but persists 
into adulthood.  The majority of progenitors within
 
this germinal matrix are glial precursors 
that generate astrocytes
 
or oligodendrocytes and a rare cell will develop into both neurons 
and
 
glia (Levison et al., 1993; Levison and Goldman, 1993; Luskin et al., 1988; Price et al., 
1988).  In cerebrum and cerebellum, oligodendrocytes
 
arise postnatally from the SVZ of 
the lateral ventricles (Reynolds and Wilkin, 1988) (Levison et al., 1993; Zerlin et al., 
1995).  Oligodendrocyte progenitors
 
then migrate long distances away from these zones 
and populate
 
the developing brain to form white matter throughout the brain.   
 
4.3 Oligodendrocyte precursor cell (OPC) proliferation and differentiation 
a Oligodendrocyte precursor proliferation 
 
OPCs undergo a series of differentiation steps to give rise to mature, multipolar 
oligodendrocytes with myelin sheets.  Recently, several oligodendrocytes precursor 
markers have been discovered, including PDGF
 
receptor-α (PDGFRα, Sox10, Nkx2.2, 
Olig1/2 and PLP/DM-20 mRNA (Lu et al., 2000; Ono et al., 1995; Piao et al., 2001b; Timsit 
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et al., 1995; Timsit et al., 1992; Yu et al., 1994; Zhou et al., 2000).  OPCs are actively 
proliferating and
 
possess migratory properties.   
A number of extracellular factors have been found to influence the proliferation of OPC.  
While OPC proliferates extensively in culture in the presence of PDGF, the absence or 
withdrawal of PDGF induces immediate terminal differentiation (Noble et al., 1988; Raff 
et al., 1988).  Overexpression of PDGF-A in transgenic mice resulted in increased 
proliferation of OPC (Calver et al., 1998) whereas both the ligand (PDGF-A) and receptor 
(PDGFRα) knockout showed a severe loss of oligodendrocytes (Fruttiger et al., 1999; 
Klinghoffer et al., 2002).  These experiments firmly established PDGF-PDGFRα ligand-
receptor pair as one major regulator of OPC proliferation.  The basic fibroblast growth 
factor (bFGF) is also a major inducer of OPCs proliferation (Villa et al., 2000) and the 
combined action of PDGF and bFGF can keep OPC in a proliferative state almost 
indefinitely in vitro (Bogler et al., 1990).   
b Oligodendrocyte precursor differentiation and maturation 
 
Oligodendrocytes differentiation and maturation takes place in the mammalian
 
CNS largely 
in early postnatal
 
life and involves morphological changes as well as expression
 
of various 
antigenic markers.  Oligodendrocyte progenitors are characterized by their bipolar
 
morphology and by the presence of specific markers such as glycolipids
 
recognized by the 
A2B5 antibody and a chondroitin sulfate proteoglycan
 
called NG2 (Nishiyama et al., 
1999).  After their migration in the mammalian CNS, oligodendrocyte progenitors settle 
along fiber tracts of the future white matter and then transform
 
into preoligodendrocytes 
(Figure 7), multiprocessed cells which
 
keep the property of cell division and express the 
sulfatide O4 on their cell surface (Sommer and Schachner, 1981).  At this stage, they are 
less motile (Orentas and Miller, 1996), or even postmigratory
 
(Pfeiffer et al., 1993a), and 
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they lose their mitogenic response to PDGF as  a consequence of PDGFR downregulation 
(Hart et al., 1989; Pringle and Richardson, 1993).  The preoligodendrocytes become 
immature oligodendrocytes, characterized in the rat by a multiramified morphology, the 
appearance of the marker galactocerebroside (GalC)
 
and the loss of expression of A2B5 
antigens on the cell
 
surface.  CNP, the earliest known myelin-specific protein to
 
be 
synthesized by developing oligodendrocytes, is expressed at the
 
same time as GalC 
(Pfeiffer et al., 1993b; Reynolds and Wilkin, 1988; Sprinkle, 1989).  Myelin-specific 
protein expression such as such as myelin basic protein (MBP), PLP and myelin associated 
glycoprotein (MAG) occurs 2-3 days after CNP expression, before myelin formation (Butt 
et al., 1995; Dubois-Dalcq et al., 1986; Hardy and Reynolds, 1993; Monge et al., 1986; 
Pfeiffer et al., 1993a).  Then the number of processes is reduced in the mature 
oligodendrocytes together with the expression of myelin oligodendrocyte glycoprotein 
(MOG), the latest marker of oligodendrocyte maturation (Hardy et al., 1996).  The mature 
oligodendrocytes will myelinate if the processes contact an axon.  The capacity
 
of 
oligodendrocyte progenitors to differentiate into oligodendrocyte, is a carefully 
orchestrated event in vivo to ensure timely myelination of the axons, and
 
is intrinsic to the 
lineage (Temple and Raff, 1986).  In fact, in the absence of neurons, MOG-positive 
oligodendrocytes can clearly make a myelin-like membrane (Sarlieve et al., 1983).  
Nevertheless, coculture with neurons increases myelin gene expression,
 
such as MBP, PLP, 
MAG (Matsuda et al., 1997).  A similar myelin-gene induction by neuronal contact with 
oligodendrocytes is also observed in vivo (Kidd et al., 1990); in premyelinating 
oligodendrocytes, axonal contact induces the switch from DM-20 to PLP
 
isoform 
expression. 
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Because mature oligodendrocytes cannot migrate,
 
preventing premature differentiation of 
progenitors is crucial
 
for ensuring that they successfully make it to their final destination.  
Premature oligodendrocyte differentiation is effectively prevented
 
by an inhibition 
mechanism recently shown to occur in gliogenesis,
 
the Notch pathway (Wang et al., 1998).  
Notch activation generally leads to the expression of Hes family inhibitory basic bHLH 
transcription factors which inhibit terminal differentiation of optic nerve OPC (reviewed by 
Kageyama and Nakanishi 1997).  Thus, Notch acts as a negative signal for OPC 
differentiation in vivo.  The expression of Jagged, a neuronal Notch ligand, is 
downregulated while embryonic development progresses, allowing myelination to occur in 
a controlled manner (Wang et al., 1998). 
Two transcription factors necessary for oligodendrocyte terminal differentiation, Sox10 
and Nkx2.2, have recently been discovered. (Stolt et al., 2002; Xu et al., 2000; Zhou et al., 
2000).  Studies in knockout mice revealed that loss of either Sox10 or Nkx2.2 results in 
hypomyelination and loss of mature oligodendrocyte markers such as PLP and MBP 
without affecting the development of oligodendrocyte precursors (Qi et al., 2001; Stolt et 
al., 2002). 
Recently, it was reported that the neurotransmitter adenosine released during action 
potential firings could potently inhibit OPC proliferation while promoting their terminal 
differentiation and myelination (Stevens et al., 2002). 
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Figure 7:  Developmental stages of cells of the oligodendrocyte lineage.  Schematic drawing of the 
morphological and antigenic progression from precursor cells to myelinating mature oligodendrocytes, 
through progenitors, preoligodendrocytes, and immature non myelinating oligodendrocytes.  Timing of 
neuronal and astrocytic signaling is indicated.  Stage-specific markers are boxed.  RNAs are in italics. 
[Modified from (Lubetzki, 1997)] 
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Chapter 2:  SPECIFIC AIMS  
 
In contrast to the well-studied neuronal α-synuclein pathology, both causes and effects of 
oligodendroglial -synucleinopathy in MSA are more enigmatic.  While the presence of -
synuclein in GCIs was
 
identified almost one decade ago, we still do not know with
 
certainty if and how -synuclein provokes the disease.  In mature brain, oligodendrocytes 
express undetectable levels of α-synuclein (Miller et al., 2005; Solano et al., 2000a).  Thus, 
ectopic expression of α-synuclein could be causally linked to MSA pathology.  To test the 
hypothesis that α-synuclein expression in oligodendrocytes leads to the formation of GCIs, 
transgenic mouse models were developed.  Although key features of MSA pathology were 
recapitulated in transgenic animal models, neither model as yet yields any specifics on how 
α-synuclein aggregates in MSA and selectively injures or kills oligodendrocytes.  In 
particular, questions remain regarding the role of α-synuclein fibrils, protofibrils, 
oligomers, GCIs, ubiquitination, and α-synuclein-interacting proteins in oligodendrocyte 
dysfunction and cell death.   
 
The aim of my PhD thesis was to further clarify these complex issues and to investigate the 
molecular mechanisms leading to oligodendroglial α-synucleinopathy and its cellular 
consequences.  Therefore, I developed an experimental system based on overexpression of 
human α-synuclein in primary mouse oligodendrocytes.  In this context, the following 
questions were addressed: 
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1. When during oligodendrocyte differentiation is transgenic α-synuclein expressed in 
primary mouse oligodendrocytes derived from (PLP)-α-synuclein transgenic mice? 
2. What are the cellular consequences of α-synuclein expression on transgenic 
oligodendrocytes? 
3. What is the contribution of an impairment of the oligodendroglial ubiquitin-
proteasome system to the pathogenesis of MSA? 
4. Do high α-synuclein levels reached by lentiviral delivery lead to the aggregation of 
ectopic α-synuclein? 
5. To what extent do α-synuclein aggregates in culture resemble GCIs found in MSA 
patients? 
6. What are the cellular consequences of α-synuclein aggregation for affected 
oligodendrocytes? 
7. Can anti-aggregative gene therapy reduce α-synuclein mediated cytotoxicity? 
8. Which molecular mechanisms induce death of affected oligodendrocytes in culture?  
Could these mechanisms also be responsible for glial cell loss in MSA? 
 
The establishment of a cell culture model of MSA is easier to manipulate than transgenic 
animals and should provide us with an experimental system to investigate the risk factors 
which may enhance and/or accelerate α-synuclein aggregation and the molecular 
mechanisms underlying oligodendrocyte cell death in MSA.  Such a model provide 
avenues to evaluate many therapeutic compounds that could inhibit the formation of α-
synuclein fibrils or rescue dysfunctional oligodendrocytes in culture, with the long term 
goal of identifying drug targets for MSA treatment. 
EXPERIMENTAL PROCEDURES  
 
 45 
Chapter 3:  EXPERIMENTAL PROCEDURES 
 
Animals 
 
Homozygous transgenic (PLP)--synuclein mice were generated in which human wild-
type -synuclein was driven by a PLP promoter (Kahle et al., 2002b).  Homozygous 
transgenic mice overexpressing the enhanced green fluorescent protein under the PLP 
promotor (PLP-eGFP) mice and wild-type mice with the same genetic background were 
used as controls. 
 
Antibodies 
The following primary antibodies were used: mouse monoclonal A2B5 (IgM, American 
Tissue Culture Collection, 1:5), rabbit polyclonal anti-NG2 antibody (Chemicon, 1:100), 
mouse monoclonal O4 (IgM, Sommer and Schachner, 1:5), mouse monoclonal anti-GalC 
(IgG3, 1:10, (Ranscht et al., 1982)), mouse monoclonal anti-myelin basic protein (MBP) 
(SMI 94 Stenberger monoclonals incorporated, 1:1000), mouse monoclonal Mab42 anti--
synuclein antibody (1:1000, BD Transduction Laboratories), human-specific rat 
monoclonal -synuclein antibody (15G7, hybridoma supernatant 1:10 (Kahle et al., 2000)), 
polyclonal anti-ubiquitin (Dako, 1:100), mouse monoclonal 1510 anti-ubiquitin 
(Chemicon, 1:1000), mouse monoclonal against the -subunits of 20S proteasome 
(Affiniti, 1:100), rabbit polyclonal antibody raised against phosphorylated -synuclein at 
Ser129 ((Fujiwara et al., 2002), 1:100 for cytochemistry and 1:1000 for western blot), 
mouse monoclonal antibody Syn303 raised against
 
oxidized -synuclein ((Giasson et al., 
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2000), 1:200 for cytochemistry and 1:1000 for western blot), rabbit polyclonal anti-4-
Hydroxy-2-Nonenal (HNE) Michael adducts (Calbiochem, 1:200), polyclonal anti-hsp 70 
(Stressgen, 1:200), rabbit polyclonal anti-hsp 40 (Stressgen, 1:200), mouse monoclonal 
anti B-crystallin (MBL, 1:100), rabbit polyclonal anti 14-3-3 antibody (Cell signaling, 
1:100), rabbit polyclonal p25 antibody (gift from PH. Jensen, 1:100), rabbit polyclonal 
activated caspase 3 (PharMingen, 1:300), monoclonal anti-GFP antibody (Clontech, 
1:1000), rabbit polyclonal anti-Fas antibody (C20, Santa Cruz, 1:50 for 
immunohistochemistry), mouse monoclonal anti-Fas antibody (1:1000 for western blot, 
BD Transduction Laboratories). 
Secondary fluorescent antibodies were Alexa Fluor 488- and 594-conjugated goat anti-
mouse, rabbit or rat antibodies (Molecular Probes, 1:1000).  Peroxidase-conjugated
 
anti-
mouse, -rat and -rabbit IgGs were purchased from Sigma (1:5000). 
   
Purification and Culturing of Oligodendrocyte Precursor Cells 
 
OPCs were purified from newborn (PLP)--synuclein, (PLP)-eGFP and wild-type C57Bl 6 
mouse brain by Percoll gradient as previously described (Lubetzki et al., 1992).  Briefly, 
the primary mixed glial cultures were obtained from forebrains of 2-day-old mice.  Mice 
were killed by decapitation, and the forebrains were dissected before being dissociated, 
first mechanically and then by digestion with 0.1% trypsin (Sigma, 15min at 37°C).  Cells 
were washed in Hank‟s balanced solution (Flow Laboratories), passed through 150 and 
63mm nylon meshes and layered on a Percoll (Pharmacia) density gradient.  The 
oligodendrocyte progenitor -rich fraction was then washed twice by centrifugation and 
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resuspended in Dulbecco's modified Eagle medium (DMEM) (Invitrogen) containing 10% 
fetal calf serum (FCS) (Eurobio).  The cells were plated out onto 14-mm-poly-L-lysine 
(Sigma) coated glass coverslips (OSI) or plastic 24-well plates (Costar) at a density of 
50x10
3
 cells/well and cultured in a 37°C 5% CO2 incubator.  For biochemical analysis of 
α-synuclein aggregates, oligodendrocytes were plated in 35mm diameter wells, at a density 
of 800x10
3
cells/well.   
The purified oligodendrocyte progenitors were cultured in Bottenstein and Sato medium 
(BS; (Bottenstein and Sato, 1979), supplemented with 1% FCS, 1% penicillin-streptomycin 
(ATGC Biotechnologie), 10ng/ml recombinant PDGF-AA (Peprotech).  After 7 days in 
culture, the medium was switched to a differentiating medium (proliferating medium 
without PDGF). 
The purity of oligodendroglial cultures assessed by immunostaining with O4 and GalC 
antibodies ascertained that 2 days after plating, 85% of the cells were O4 positive 
immature oligodendrocytes. 
 
Lentiviral vector and primary oligodendrocyte transduction 
 
Lentiviral vectors were produced using a triple transfection system in 293T cells with the 
following plasmids: 
1. A packaging plasmid encoding structural viral proteins and enzymes.  The 
packaging signal has been deleted. 
2. An envelope plasmid encoding the envelope of vesicular stomatitis virus 
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3. A transfer plasmid encoding the transgene under control of a promoter.  It contains 
cis-acting signals for encapsidation (), reverse transcription and integration 
flanked by two long terminal repeats (LTR) 
The vector particles are released in the supernatants and were isolated by 
ultracentrifugation.  The vectors are pseudotyped with the envelope of VSV to increase 
tropism and stability of the vectors.  Lentiviral vectors produced by this method are able to 
transduce non-dividing cells such as neurons and oligodendrocytes.  The backbone of 
recombinant lentiviral vectors expressing eGFP (LV-eGFP), -synuclein (LV-SYN) and 
-synuclein (LV-SYN) under the mouse phosphoglycerate kinase promoter (PGK) was as 
follow: 
 
 
 
Viral stocks were concentrated 10-fold and the biologic titers of concentrated vector 
preparations ranged between 1-3x10
8
 Infecting Unit/mL.  After 7 days in culture, when 
about 80% of the cells were O4-positive, oligodendrocyte progenitors were exposed to 
lentiviral vectors at the doses of 50ng/L (p24 protein concentration).  The transduction 
efficiency of oligodendrocytes was about 70%.  2 days after transduction, 10 of 
proteasome inhibitor was added to the oligodendrocyte cultures for 24h.   
 
Immunostaining 
 
eGFP/ / -synuclein Mouse PGK1 SI
N  
5’LTR WPRE  
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For double immunofluorescence staining of immature oligodendrocytes cultures, involving 
surface and cytoplasmic antigens, oligodendrocytes grown on glass coverslips were 
washed once with phosphate-buffered saline (PBS), and fixed with 4% paraformaldehyde 
(Sigma) in PBS for 5min at RT.  After washing with PBS, fixed cells were blocked with 
10% FCS in PBS for 30min and incubated overnight at 4°C with the primary antibody 
(A2B5, O4 or GalC) diluted in the blocking solution. The following day, the cells were 
washed with PBS and then incubated 1h with the secondary antibody at RT.  After 
washing, cultures were fixed 10min with 4% paraformaldehyde, washed in PBS, and 
incubated with primary antibody 1h at RT with the primary antibody diluted in blocking 
solution containing 0.02% Triton-X-100 (Sigma) for cytosolic staining.  Cells were 
washed, incubated for 1h at RT with the secondary antibody and counterstained with the 
nuclear dye Hoechst 33342 (Sigma, 1g/ml).  After washing in PBS, coverslips were 
mounted in Fluoromount (Southern Biotechnology Associates). 
 For double immunostaining of mature oligodendrocytes involving only cytoplasmic 
antigens, cells were fixed with 4% paraformaldehyde in PBS for 15min at RT.  After 
washing with PBS, fixed cells were blocked with 10% FCS in PBS for 30min and 
incubated 1h at RT with the primary antibody diluted in blocking solution containing 
0.02% Triton-X-100.  Cells were washed with PBS, incubated with the secondary antibody 
1h at RT and counterstained with Hoechst dye before mounting.   
For quantification analysis, cells were visualized with Eclipse TE300 Microscope 
fluorescence microscope (Nikon) using 20X or 40X objectives, and phase contrast 
microscopy with 40X objective, as indicated.  Images were acquired with Simple PCI 
software (Compic Inc. Imaging Systems).  
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To demonstrate simultaneous immunocytochemical localization, cells were visualized 
using 63X or 100X oil-immersion objectives with axioplan 2 imaging Zeiss Microscope or 
with LSM510 Zeiss confocal microscope.  Images were acquired with FluoUp Mercator 
software (Explora Nova) and LSM 10 Meta (Zeiss), respectively. 
Thioflavin S Staining 
 
Cells were washed once with PBS, fixed 30min with 4% paraformaldehyde and subjected 
to immunofluorescence staining as described above.  After three PBS washes, cells were 
incubated with 0.005% thioflavin S (diluted in 70% ethanol, Sigma) for 8min,  washed 
three times in ethanol 70%, once in H2O, and then mounted.   
 
Histochemistry on human brains 
Sections from either formalin or ethanol-fixed paraffin-embedded brain tissue, as well as 
frozen tissue from MSA cases and controls, were obtained from the German Brain Bank 
"Brain-Net" and the Center for Neurodegenerative Disease Research, University of 
Pennsylvania.  For immunohistochemistry, the avidin-biotin-peroxidase method with 3,3'-
diaminobenzidine for color development or the alkaline phosphatase/anti-alkaline 
phosphatase system (DAKO, Germany) with neufuchsin as the chromogen were used.  To 
enhance immunoreactivity, tissue sections were boiled in 10 mM citrate buffer, pH 6.0, in 
a microwave oven (5 times for 3min each). To block non-specific antibody binding sites, 
tissue sections were incubated in 2% BSA / 0.01% (v/v) Triton X-100 for 30min at room 
temperature.  An improved thioflavin S staining method (Guntern et al., 1992) was 
performed.  Double-labeling immunfluorescence of Fas and a-synuclein was performed 
with Alexa Fluor 488-conjugated goat anti-rabbit and Alexa Fluor 594-conjugated goat 
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anti-mouse (Molecular Probes, 1:1000) as secondary antibodies. Autofluorescence was 
blocked by incubating the sections with 0.3 % Sudan Black in 70% ethanol (Romijn et al., 
1999). Sections were mounted in Vectorshield with DAPI (Vector Laboratories).  
 
Immunoelectron Microscopy 
Immunogold labeling for electron microscopy was performed on oligodendrocytes 
overexpressing either eGFP or wild-type -synuclein.  After 8-10 days in culture, some of 
the oligodendrocytes were treated with proteasome inhibitor for 24h.  Cells were then 
rinsed with PBS, fixed with 4% paraformaldehyde for 45min, washed three times in PBS 
then incubated for 1h in PBS, 0.2% BSA, 0.02% gelatine blocking buffer.  Cells were 
rinsed three times with 0.2M PBS and incubated overnight at 4°C with 15G7 (1:10) in 
PBS, 0.2% BSA.  The day after, the cells were extensively washed with filtered PBS and 
incubated 3h at RT with goat anti-rat immunoglobulins conjugated to 10nm gold particles 
(British Biocell, 1:100).  To determine background staining, 15G7 antibody was omitted.  
Cells were then washed in PBS, fixed 30min with 2% glutaraldehyde, and then postfixed in 
1% osmium
 
tetroxide for 30min on ice in the dark.  Cells were washed in distilled water, 
dehydrated in
 
a graded series of ethanol solutions in the specific order: ethanol 50% (5min) 
and ethanol 70% (5min).  Cells were treated with uranyl acetate 1% in 70% methanol 
30min (in the dark) and bathed 5min in ethanol 95% (5min). Oligodendrocytes were pre-
embedded in a mix ethanol/epon (ratio 2/1 for 5min; and then switched to 1/1 for 5min, 
then to a ratio of 1/2 for 5min).  Cells were then embedded in Epon (2 baths in pure epon 
for 5min each followed by a 24h polymerization step at 60°C). Semi-thin sections 
(0.10m) were cut with an ultramicrotome, counterstained with toluidine blue.  When the 
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cell layer was reached, ultra-thin sections (50-60nm) were laid on a copper grid and 
counterstained with conventional techniques (uranyl acetate and lead citrate). 
Sections were examined with a JEOL 1200EX II transmission electron microscope.  
Images were analyzed with Analysis Docu Soft Imaging System. 
Proteasome Inhibition 
 
Differentiated oligodendrocytes were exposed to 0.01-10 epoxomicin or MG-132 
(Calbiochem) for 2-24h.  After the indicated time, cells were fixed and stained with 15G7 
for visualization and quantification of -synuclein aggregates.  The composition of -
synuclein aggregates was characterized by double staining for -synuclein (normal, 
nitrated or phosphorylated -synuclein), HNE, ubiquitin, 20S proteasome subunits, hsp70, 
hsp40, B crystallin, 14-3-3 chaperone protein, tubulin polymerization promoting protein 
TPPP/p25 protein.  Cells were counterstained with Hoechst nuclear dye as described 
above.   
 
Quantification of -synuclein Inclusions 
 
Punctate aggregates were detected as many small sized--synuclein positive inclusions 
throughout the cytosol, whereas the GCI-like inclusions were single, compact and 
perinuclear.  For each condition, 500 oligodendrocytes from randomly selected fields were 
analyzed in triplicates and each experiment was repeated at least three times. 
 
Quantification of Ubiquitinated Cytoplasmic Inclusions 
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To determine the number of oligodendrocytes containing ubiquitinated cytoplasmic 
inclusions, cells were stained with polyclonal anti-ubiquitin antibody and visualized under 
standard epifluoresence using 40X objective. Inclusions were scored as positive if the 
ubiquitin immunoreactivity was localized to a discrete area, distinct from the nucleus, not 
encompassing the entire cytoplasmic volume.  For each condition, 500 oligodendrocytes 
from randomly selected fields were analyzed in triplicates and each experiment was 
repeated three times. 
 
Treatment with Caspase Inhibitors 
 
After 2 weeks in culture, the medium was replaced with BS medium containing the broad 
spectrum caspase inhibitor z-VAD-fmk or specific inhibitors z-DEVD-fmk, z-IETD-fmk 
and z-LEHD-fmk against caspases-3,-8 and -9, respectively (Calbiochem; final 
concentration 300).  Each compound was added to 3 separate wells.  Control cultures 
were returned to BS medium in the absence of caspase inhibitors.   
Cultures were incubated for 20min and treated with 10 epoxomicin (or BS medium for 
control cultures) at 37°C 5% CO2 for a further 24h, fixed using 4% paraformaldehyde in 
PBS and immunostained for -synuclein, activated caspase-3 and counterstained with 
Hoechst nuclear dye. 
 
Treatment with Death Ligands 
 
Oligodendrocytes were cultured as described above and then treated for 18h with soluble 
Fas ligand (sFasL; 5ng/mL, Upstate), membrane bound Fas ligand (mFasL; 5ng/mL, 
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Upstate), mouse NGF (100ng/mL, Alomone Labs), TNF (100ng/mL, Chemicon), TRAIL 
(300ng/mL, Chemicon) and sometimes preincubated with neutralizing Fas antibody 
(1g/mL Alexis).  Cells were stained with propidium-iodide and calcein (Live dead kit, 
Molecular Probes).  Cells were scored as alive if the cytosol was intensely stained with 
calcein and as apototic if the nucleus was red.  For each condition, 5 randomly selected 
fields of 100 oligodendrocytes were analyzed in triplicates and the experiment was 
repeated three times. 
 
Caspase-3 Activation 
 
Cultured oligodendrocytes were treated as described above and then immunocychemically 
stained with anti-activated caspase-3 antibody to detect caspase-3 activation.  Cells were 
scored as positive if the cytosol was intensely activated-caspase-3 immunoreactive.  For 
each condition, 5 randomly selected fields of 100 oligodendrocytes were analyzed in 
triplicates and each experiment was repeated at least three times. 
 
Visualization of Apoptotic Nuclei 
 
Cells were scored as apoptotic based on Hoechst staining showing condensed or 
fragmented chromatin and nuclear morphology. To quantify apoptotic cell death, the 
percentage of cells with condensed and fragmented chromatin nuclei in 5 fields of 100 
cells was determined.  Each experiment was conducted at least three times. 
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Fractionation of -synuclein Aggregates 
 
Sequential detergent soluble extraction (Baba et al., 1998; Dickson et al., 1999; Kahle et 
al., 2001) was used to detect insoluble α-synuclein molecules after treating transgenic 
oligodendrocytes with epoxomicin.  Briefly, mature (PLP)--synuclein and (PLP)-eGFP 
oligodendrocytes were exposed to epoxomicin (10) for 24h , washed twiced with cold 
PBS and harvested on ice in Tris-buffered saline (TBS) + -glycerophosphate (50mM) and 
sodium orthovanadate (1mM), complete protease inhibitors (Roche).  The cells were 
sonicated and the cytosolic fraction was isolated after centrifugation. Equal amount of 
protein from both control and epoxomicin treated cultures was determined by the Bradford 
Protein Assay (Bio-Rad) and the 100,000 xg pellet was extracted in 5% sodium 
dodecylsulfate (SDS).  The remaining detergent insoluble pellet was solubilized with 8M 
urea / 5% SDS. 
The fractions were loaded onto a 15% SDS polyacrylamide gel (15% SDS-PAGE), 
separated electrophoretically, and transferred to polyvinylidene difluoride (PVDF) 
membranes (Millipore).  The PVDF membranes were briefly washed in methanol, blocked 
for 1h at RT with TBS containing 1.0% Tween-20 and 5% dehydrated skim milk to block 
nonspecific protein binding, and probed overnight at 4°C with anti--synuclein 
monoclonal antibodies 15G7, Syn303, phosphorylated -synuclein polyclonal antibodies 
and monoclonal anti-GFP. 
Changes in ubiquitination were visualized by probing the membranes with anti-ubiquitin 
1510 monclonal antibody.   
After several washes, the membranes were incubated with horseradish peroxydase 
conjugated secondary antibodies, and after additional washes, the immunoreactive bands 
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were visualized using an enhanced chemiluminescence detection system (Amersham 
Pharmacia Biotech).  Membranes were exposed to Kodak X-ray films. 
 
Biochemistry for Fas expression 
 
Cells were washed 2 times with PBS before being lysed 20min on ice in STEN lysis buffer 
containing 50mM Tris pH 7.6, 2mM EDTA, 0.2% (v/v) NP-40 und 150mM NaCl.  Cells 
were centrifuged 20min at 16 000 xg at 4°C.  Protein concentration was determined with 
Bradford test and 30g of total protein was loaded on a 15% SDS gel.  MSA and control 
brains were homogenized on ice with a glass potter in STEN lysis buffer and homogenates 
were briefly sonicated and centrifuged 20min at 16 000 xg at 4°C.  Protein concentration 
was determined with Bradford test and 80g of total protein was loaded on 15%SDS gel.  
Western blot was performed as described above and changes in Fas expression levels were 
visualized by probing the membranes with anti-Fas monclonal antibody (Transduction 
Laboratories), and equal loading was confirmed by reprobing with mAb B-5-1-2 against -
tubulin (Sigma). 
Frozen tissue from MSA cases and controls were obtained from the German Brain Bank 
"Brain-Net".  Brain samples were homogenized on ice with a glass potter in STEN lysis 
buffer and homogenates were briefly sonicated and centrifuged for 20min with 16,000 x g 
at 4°C.  Protein concentration was determined with Bradford test and 80g of total protein 
was subjected to 15% SDS-PAGE.  Western blot analysis was performed as described 
above.   
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Proteasome activity  
 
The proteasome activity was determined as described (Lightcap et al., 2000).  Proteasome 
activity was measured 8 days after differentiation.  Oligodendrocytes cultured with 
proteasome inhibitors or left untreated were washed twice wit PBS and harvested on ice in 
25mM Tris buffer.  Cells were centrifuged and lysed by brief sonication and the 
fluorogenic substrates Suc-LLVY-AMC, Z-LLE-AAMC and Boc-LRR-AMC, were added 
to measure the chymotryptic-like, tryptic-like and post-acidic activities, respectively.  The 
proteasome activities were monitored by the fluorescence activity (ex: 380 nm; em: 460 
nm) (Keller et al., 2000).  The relative activity was standardized by protein concentration 
which was determined using the Bio-Rad assay kit (Bio-Rad laboratories, CA). 
Statistical Analysis 
 
Student‟s t tests and one-way ANOVA followed by Dunnett‟s test were used to determine 
whether differences between groups were significant.  Data are expressed as means +/- 
SEM of at least three independent experiments performed in triplicates.  Statistical 
significances were defined as *P< 0.05; **P< 0.001; ***P< 0.0001. 
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Chapter 4:  RESULTS 
 
1 Transgenic -Synuclein Expression in Primary Oligodendrocytes 
Derived From (PLP)--synuclein Mice 
 
To determine when during oligodendrocyte differentiation is transgenic α-synuclein 
expressed in culture, I isolated neuroglial progenitor cells from (PLP)--synuclein mice, 
and induced the oligodendroglial lineage by mitogen deprivation (Lubetzki et al., 1992).  
Oligodendrocyte differentiation in these cultures was monitored by immunostaining with 
stage-specific markers, including the cell surface protein A2B5, the chondroitin sulphate 
proteoglycan NG2, the ganglioside O4 and GalC, and the integral MBP.  The primary 
cultures were highly enriched in oligodendrocyes, with 80-85% of the cell population 
being O4-positive. 
Transgenic -synuclein expressed under control of the PLP promoter was 
detectable already in A2B5- and NG2-positive oligodendrocyte precursors (Figure 8), 
consistent with the very early induction of the DM-20/PLP gene in vivo (LeVine et al., 
1990).  Expression of the transgenic -synuclein persisted throughout oligodendrocyte 
differentiation in culture (Figure 8), as evidenced by human-specific -synuclein 
immunoreactivity in the O4-positive immature stage, the GalC-positive mature stage, and 
the myelin basic protein positive pre-myelinating stage.  Specificity of the human -
synuclein 15G7 antibody was demonstrated by the absence of immunostaining in primary 
oligodendrocytes derived from (PLP)-eGFP transgenic mice. 
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Figure 8:  Oligodendrocyte progenitor cells were isolated from transgenic mouse forebrains.  After 
being cultured for 2, 7, 11 and 17 days, primary -synuclein transgenic oligodendrocytes were fixed for 
double-labeled immunostaining analysis with the indicated oligodendrocyte markers (green; upper 
panels) and 15G7 anti--synuclein (red; lower panels).  Diffuse -synuclein staining was detected 
throughout the cytoplasm and the processes from the oligodendrocyte progenitor stage throughout the 
maturation process.  Scale bars, 10m. 
 
 
2 Cellular Consequences of -synuclein Expression on Transgenic 
Oligodendrocytes  
 
Compared to wild-type and control eGFP transgenic oligodendrocytes, the number of 
A2B5-positive precursor cells decreased about 2 days earlier in -synuclein transgenic 
cultures, concomitant with an equally accelerated appearance of O4-positive immature 
oligodendrocytes (Figure 9).  The effect of transgenic -synuclein on oligodendrocyte 
maturation was less marked.  The development of -synuclein transgenic GalC-positive 
mature oligodendrocytes was accelerated by approximately 1 day, and no effect of -
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synuclein was observed when measuring the appearance of MBP-positive pre-myelinating 
oligodendrocytes after 2 weeks in culture. 
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Figure 9:  Oligodendrocyte progenitor cells isolated from -synuclein (solid lines) and eGFP (broken 
lines) transgenic mice were kept in culture for up to 21 days and labeled with oligodendrocyte markers 
(black=A2B5; blue=O4; green=GalC; red=MBP).  An accelerated differentiation could be observed in 
-synuclein transgenic oligodendrocytes. 
 
Rat oligodendrocyte cultures have been reported to withdraw from the cell cycle and 
differentiate faster from the A2B5-positive progenitor stage along the oligodendroglial 
lineage upon partial proteasome inhibition with low doses of lactacystin and MG-132 
(Pasquini et al., 2003).  -synuclein expression decreased proteasome activity in cell lines 
(Tanaka et al., 2001), possibly because -synuclein fibrils directly inhibit the 20S 
proteasome (Lindersson et al., 2004; Snyder et al., 2003).  Therefore the effects of ectopic 
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-synuclein expression on oligodendrocyte proteasomal activities were addressed by 
measuring the hydrolysis rates of fluorogenic proteasome substrates in non-transgenic as 
well as eGFP and -synuclein transgenic oligodendrocytes.  No significant difference in 
any proteasomal activity was observed in eGFP transgenic oligodendrocytes compared to 
non-transgenic oligodendrocytes.  Interestingly, primary -synuclein oligodendrocytes 
showed a significant decrease in the chymotryptic proteasomal activity (Figure 10).  The 
tryptic and postacidic proteasomal activities were reduced to a lesser extent in -synuclein 
transgenic oligodendrocytes.  Consistently, aggregated preparations of recombinant -
synuclein selectively inhibited the chymotryptic activity of 20S proteasomes in vitro 
(Lindersson et al., 2004), but the mechanism of such an unusual inhibition of the 
chymotryptic proteasome activity by -synuclein remains to be rigorously established. 
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Figure 10:  Primary wild-type, eGFP and -synuclein transgenic oligodendrocytes were cultured for 2 
weeks and lysed.  The fluorogenic substrates Suc-LLVY-AMC, Z-LLE-AAMC and Boc-LRR-AMC, 
were added to measure the chymotryptic-like, tryptic-like and post-acidic activities, respectively and 
changes in proteasome activities were determined as percentage of proteasome activities in wild-type 
oligodendrocytes.  Data are expressed as means +/- SEM of at three independent experiments performed 
in triplicates.  Student t test; **P<0.001. 
3 Influence of UPS Impairment on Oligodendroglial -
Synucleinopathy  
3.1 Proteasome inhibition causes time- and dose-dependent formation of α-
synuclein inclusions in transgenic oligodendrocytes 
 
To exacerbate the inhibition of the chymotryptic proteasome activity in -synuclein 
transgenic oligodendrocytes and to determine the contribution of an impairment of the 
oligodendroglial UPS to the pathogenesis of MSA, I challenged primary oligodendrocytes 
with the epoxyketone epoxomicin.  In the absence of inhibitor, the transgenic -synuclein 
in primary oligodendrocytes was diffusely distributed throughout the cytosol and the 
processes.  Under basal conditions, -synuclein aggregates were rarely seen under the 
microscope (5% of total -synuclein transgenic oligodendrocytes), indicating that -
synuclein expression in primary oligodendrocytes derived from (PLP)--synuclein mice is 
not enough to induce MSA neuropathology.  However, after a 2h treatment with a 
saturating concentration of epoxomicin (10), small -synuclein aggregates developed 
throughout the cytosol of the oligodendrocytes (Figure 11).  Between 6-12h of proteasome 
inhibition, the small aggregates clustered into larger aggregates, which later appeared to 
converge into a single round or triangular -synuclein aggregate near the nucleus (Figure 
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11).  I confirmed specificity of the observed effects with a different proteasome inhibitor, 
the peptide aldehyde MG-132 (Kisselev and Goldberg, 2001).   
0h 2h 6h
12h 24h 24h  
Figure 11:  Cultures were treated with 10 of epoxomicin for the indicated times.  Transgenic 
human -synuclein aggregates was detected by immunostaining with 15G7 antibody and visualised by 
confocal microscopy.  Note the time-dependent changes in -synuclein localization from diffuse in the 
cell body and processes (0h) to small aggregates scattered throughout the cytosol after 2h (arrows) to 
large perinuclear aggregates after 24h (arrowheads).  Scale bar, 10. 
 
Quantitative dose-response analysis showed that the number of oligodendrocytes with 
several small -synuclein aggregates increased from 5.5% ± 1.1 in control cultures to 
19.8% ± 3 in the presence of 0.01 epoxomicin.  Exposure to higher doses of 
proteasome inhibitor (0.1-10) was accompanied with a gradual decrease of 
oligodendrocytes with small -synuclein aggregates concomitant with a dramatically 
increased formation of large perinuclear aggregates in up to 42.5% ± 2.5 of the 
oligodendrocytes (Figure 12).  
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Figure 12:  Primary -synuclein transgenic oligodendrocytes were treated with 0-10 epoxomicin 
for 24h.  Cells were then stained with 15G7 anti--synuclein antibody and the number of 
oligodendrocytes containing small or large -synuclein aggregates were counted under standard 
epifluoresence.  Small aggregates were scored when detected as several small sized--synuclein 
immunopositive inclusions throughout the cytosol, whereas the large inclusions were single, compact 
and perinuclear.  For each condition, 500 oligodendrocytes from 3 randomly selected fields were 
analyzed.  Data are expressed as means from 5 independent experiments conducted in triplicate.  The 
asterisks indicate statistical differences between the percentages of primary -synuclein transgenic 
oligodendrocytes bearing aggregates when treated with epoxomicin compared with control (0) 
conditions.  Student t test; *p< 0.05; **P<0.001. 
 
3.2 Proteasome inhibition elevates α-synuclein levels and induces the 
formation of detergent insoluble α-synuclein inclusions 
 
Although it is not clear if -synuclein is directly degraded by the proteasome in a 
ubiquitin-dependent manner (Bennett et al., 1999; Tofaris et al., 2001), it was shown 
previously that proteasome inhibition in neuronal cells causes the formation of insoluble, 
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ubiquitinated -synuclein aggregates (Rideout et al., 2004; Rideout et al., 2001).  To assess 
the influence of proteasome inhibition on -synuclein turnover and solubility in 
oligodendrocytes, differentiated primary oligodendrocyte cultures treated with epoxomicin 
were lysed.  The lysates were fractionated into buffer-soluble, SDS-soluble, and SDS-
insoluble material (urea extract) (Kahle et al., 2002b), and Western blot analysis was 
performed with antibodies against -synuclein. 
In control cultures derived from eGFP transgenic mouse oligodendrocytes, only small 
amounts of endogenous -synuclein were detected, consistent with a previous report on 
wild-type rat oligodendrocytes (Richter-Landsberg et al., 2000).  Endogenous -synuclein 
migrated as a single band with an apparent molecular mass of 16kDa, corresponding to 
monomeric -synuclein, and was found in the buffer-soluble (cytosolic) fraction (Figure 
13A).  Treatment with 10µM epoxomicin raised the steady-state level of soluble, 
monomeric -synuclein (Figure 13A), demonstrating that -synuclein is turned over by the 
proteasome in primary oligodendrocytes.  There was no formation of insoluble -synuclein 
aggregates in eGFP-transgenic oligodendrocyte cultures even in the presence of saturating 
concentrations of epoxomicin.  In contrast, -synuclein transgenic oligodendrocytes 
contained considerable amounts of buffer-insoluble -synuclein in the SDS fraction.  
However, -synuclein transgenic oligodendrocytes did not contain detectable amounts of 
detergent-insoluble -synuclein in the absence of proteasome inhibitor.  Steady-state levels 
of transgenic human -synuclein in these cultures were greatly increased upon proteasome 
inhibition, and a rather large proportion of -synuclein could only be recovered under 
harsh denaturing detergent conditions (extraction with 8M urea / 5% SDS) (Figure 13B).  
Much of the SDS-insoluble, -synuclein-immunoreactive material migrated as >40kDa 
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high molecular weight smear, and was previously shown to be characteristic for human 
MSA patients (Campbell et al., 2001; Kahle et al., 2002b).  Taken together, proteasome 
inhibition in primary -synuclein transgenic oligodendrocytes causes the formation of 
inclusions containing insoluble -synuclein aggregates.  
 
 
 
Figure 13:  (A, B)  Transgenic -synuclein primary oligodendrocytes were challenged without (-) or 
with 10 epoxomicin for 24h and washed twice with cold PBS.  Cells were then fractionated into 
TBS-soluble, SDS-soluble and urea extracts.  These fractions were electrophoresed and Western blotted, 
and probed with Mab42 anti--synuclein (A), and human-specific 15G7 anti--synuclein (B) 
 
 
4 High Levels of -Synuclein are Sufficient to Induce the Formation of 
Inclusions in Primary Oligodendrocytes 
 
Most likely epoxomicin treatment elevates the -synuclein levels beyond a threshold 
above which spontaneous aggregation of -synuclein occurs.  To corroborate this point, 
primary wild-type oligodendrocytes were transduced with a lentiviral vector encoding -
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synuclein, which has been previously demonstrated to cause degeneration in dopaminergic 
nigral neurons in the rat brain (Lo Bianco et al., 2002).  As controls lenti-eGFP, and more 
specifically, a novel lentiviral construct encoding the non-amyloidogenic -synuclein were 
used. 
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Comparative Western blotting revealed that human -synuclein expression levels in 
primary mouse oligodendrocytes 2 days after transduction with a lentiviral vector were 
much higher than the basal levels detected in primary oligodendrocytes derived from PLP-
-synuclein transgenic mice (Figure 14A).  Thus, acute lentiviral expression of -
synuclein driven by a PGK promoter is stronger compared to transgenic expression in the 
(PLP)--synuclein mouse derived oligodendrocytes.  Importantly, a considerable fraction 
of the -synuclein transduced into wild-type oligodendrocytes was recovered from the 
SDS-insoluble fraction even in the absence of proteasome inhibitor (Figure 14B).  Thus, 
lentiviral vectors allow high-level overexpression of -synuclein without potential side 
effects due to proteasome inhibition. 
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Figure 14:  (A)  Primary oligodendrocyte cultures derived from (PLP)--synuclein transgenic (tg) 
mice were challenged without (-) or with 10M epoxomicin for 24h and wild-type derived 
oligodendrocytes were exposed for 2 days to LV-SYN, as indicated.  Cells were then fractionated into 
TBS-soluble.  These fractions were electrophoresed and Western blotted, and probed with human-
specific 15G7 anti--synuclein.  (B)  Similarly high levels of -synuclein were expressed after 1 day 
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epoxomicin of transgenic (PLP)--synuclein oligodendrocytes and 2 days after transduction of wild-
type mouse oligodendrocytes with LV-SYN.  Cultures were lysed and Western probed with human-
specific 15G7 antibody. 
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Two days after transduction, lentivirally delivered eGFP and -synuclein was evenly 
distributed throughout the cytosol of O4-positive primary wild-type mouse 
oligodendrocytes (Figure 15A).  In contrast, a significant fraction of the O4-positive 
oligodendrocytes transduced with LV-SYN showed perinuclear inclusions similar to 
those found in epoxomicin-treated -synuclein transgenic oligodendrocytes (Figure 15A, 
B).  The GCI-like fibrillar nature of these inclusions was confirmed by staining with 
thioflavin S (Figure 15B).  While 32.3 ± 5.3% of oligodendrocytes transduced with -
synuclein lentiviral vectors developed cytoplasmic inclusions, less than 10% contained 
cytosolic aggregates in control cultures exposed to LV-eGFP and LV-SYN (Figure 15B). 
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Figure 15:  (A)  Wild-type mouse oligodendrocytes were transduced with recombinant lentiviral 
vectors harboring eGFP, -synuclein, and -synuclein, as indicated.  Two days after transduction, 
oligodendrocytes were identified by O4 staining (left panels) and eGFP, -synuclein or -synuclein 
immunostained (middle panels).  Note that the few (O4-negative) astrocytes present in the cultures were 
also transduced by the lentiviral -synuclein vector, but in these cells -synuclein did not form GCI-like 
inclusions.  Nuclei were counterstained with Hoechst 33258 (blue; right panels).  Scale bar, 10m.  (B)  
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Lentiviral mediated -synuclein expression was sufficient to induce the formation of cytoplasmic 
inclusions while eGFP and -synuclein transduced oligodendrocytes hardly developed any inclusions. 
 
 
5 Inclusions Formed in Culture Resemble Human Pathological GCIs 
5.1 Characterization of the inclusions formed in vitro 
 
The resemblance in morphology between -synuclein inclusions in primary 
oligodendrocytes and GCIs in MSA is striking, as evidenced by the picture below: 
 
Figure 16:  Treatment of -synuclein transgenic primary oligodendrocytes with proteasome inhibitors 
caused the formation of -synuclein inclusions that resembled human pathological GCIs. Scale bar, 
10m. 
 
To characterize the nature of these -synuclein aggregates and to determine their degrees 
of homology with human GCIs, I decided to perform a thoroughful and lengthy analysis of 
these inclusions using established markers of GCI pathology. 
 
Long before -synuclein was found to be the main component of GCIs, ubiquitin was the 
reference marker of the glial inclusions found in MSA (Papp et al., 1989b).  Biochemical 
MSA model MSA patient 
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analysis of the inclusions found in vitro revealed that they also contain ubiquitin.  In fact, 
high molecular mass protein smears reacted with anti-ubiquitin on Western blots of the 
detergent-insoluble fractions prepared from epoxomicin-treated (PLP)--synuclein 
oligodendrocytes (Figure 17A).  Moreover, double-label confocal microscopy 
demonstrated co-localization of -synuclein and ubiquitin within the inclusions that 
formed in proteasome-inhibited transgenic oligodendrocytes (Figure 17B, C), while 
oligodendrocytes not challenged with epoxomicin exhibited low-level and diffusely 
distributed ubiquitin immunoreactivity throughout the cytosol.  Ubiquitin 
immunoreactivity was intense in the inner area of the small aggregates (Figure 17B).  
Interestingly, in the large perinuclear aggregates, ubiquitin immunoreactivity displayed 
spatial variations in intensity so that some regions of an individual aggregate were 
intensely stained, while other regions remained unstained (Figure 17C).  Quantitative 
analysis revealed that 43.7% ± 3.7 of the large perinuclear inclusions were -synuclein-
immunopositive and ubiquitin-negative, and 52.4% ± 2 were immunopositive for both 
ubiquitin and -synuclein.  The remaining 3.9% of the inclusions were detected only with 
anti-ubiquitin.  A similarly small percentage of ubiquitin-immunopositive inclusions were 
detected in proteasome-inhibited control eGFP-transgenic oligodendrocytes.  Although 
ubiquitin is often used as a marker of GCIs (Kato et al., 1991; Papp et al., 1989a), only a 
subset of -synuclein-positive GCIs is ubiquitin-immunoreactive (Gai et al., 1998; 
Sampathu et al., 2003).  Taken together, ubiquitination of -synuclein is not the cause of 
aggregate formation but may rather be a secondary consequence of -synuclein 
aggregation.  Consistent with mobilization of the UPS, some of the small and large -
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synuclein aggregates in epoxomicin-treated transgenic oligodendrocytes contained 20S 
proteasome -subunits co-localizing with -synuclein (Figure 17B, C). 
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Figure 17:  (A) Urea extracts were prepared from primary (PLP)--synuclein oligodendrocyte 
cultures that were treated without (-) or with (+) 10µM epoxomicin for 1 day.  The material was Western 
blotted and probed with anti-ubiquitin, revealing the presence of high-molecular mass protein smears in the 
insoluble fraction of proteasome-inhibited oligodendrocytes.  (B-C) Colocalization of -synuclein (red) 
with ubiquitin (green) and 20S proteasome -subunits (green) in the small (B) and large (C) aggregates was 
demonstrated by dual-labeling confocal microscopy.  Nuclei were counterstained with Hoechst dye (blue).  
Scale bar, 10m. 
 
Heat shock proteins (hsps) are molecular chaperones, which directly prevent the misfolding of 
aggregation-prone proteins and thereby modulate neurodegeneration and oligodendrocyte 
damage (Muchowski and Wacker, 2005; Richter-Landsberg and Bauer, 2004).  The major 
cytosolic chaperone hsp70 and its cofactor hsp40 as well as the small hsp B-crystallin co-
localized with -synuclein aggregates in proteasome-inhibited transgenic oligodendrocytes, 
closely reflecting the accumulation of these hsps in GCIs of human MSA patients (Figure 18A-
I).  The apparent recruitment of the chaperones hsp70 / hsp40 and B-cystallin may reflect an 
adaptive cellular response to the accumulation of misfolded proteins.  
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Figure 18: (A-I)  Primary -synuclein transgenic oligodendrocytes challenged with epoxomicin were double 
labeled with antibodies against -synuclein (red) and hsp40, hsp70 and B-crystallin (green).  Yellow signal 
depicts the presence of these stress proteins in small (A, D, G) and large (B, E, H) -synuclein aggregates.  
Nuclei were counterstained with Hoechst dye (blue).  Hsp40, hsp70, and B-crystallin are also present in 
GCIs of MSA patients.  Scale bars, 10m. 
 
 
It has been suggested that the induction of B-crystallin serves to maintain the integrity of 
the microtubular network, but sustained proteasome inhibition would overwhelm the 
chaperone capacity of oligodendrocytes, leading to a disruption of the microtubular 
network that is most important for oligodendrocyte viability (Goldbaum and Richter-
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Landsberg, 2004).  In my experimental system, I did not note any obvious aberrations of 
the microtubule-associated protein tau.  However, inclusions formed in epoxomicin-treated 
-synuclein transgenic oligodendrocytes were immunopositive for the tubulin 
polymerization promoting protein p25(Figure 19A), which has been described to induce 
aberrant microtubule assemblies (Hlavanda et al., 2002) and stimulate -synuclein 
fibrillization (Lindersson et al., 2005).  Indeed, p25 immunoreactivity was detected in 
GCIs of MSA patients (Lindersson et al., 2005). 
Furthermore, the microtubular network of oligodendrocytes might be influenced by 14-3-3 
proteins.  For example, 14-3-3 was reported to bind to tau and regulate its 
phosphorylation (Hashiguchi et al., 2000).  Although there is generally no tau pathology in 
MSA patients and therefore very little overlap between tau and 14-3-3 immunoreactivity in 
GCIs (Giasson et al., 2003b), these pathological lesions do contain considerable 14-3-3 
(Kawamoto et al., 2002).  Similar to GCIs in MSA patient brains, inclusions formed in 
proteasome inhibited primary -synuclein oligodendrocytes contain 14-3-3 (Figure 19B).  
The localization of 14-3-3 in these -synuclein inclusions could simply reflect physical 
interaction between these two molecules (Ostrerova et al., 1999).  Alternatively, the 
apparent recruitment of 14-3-3 into GCIs might indicate a specific interaction with -
synuclein whose aggregation is promoted by phosphorylation.   
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Figure 19: (A, B) Co-localization of transgenic -synuclein in inclusions formed in epoxomicin-
treated primary oligodendrocytes with p25 (A) and 14-3-3 (B) is evidenced by the yellow overlay of 
red -synuclein signal and green marker signal.  Scale bar, 10m. 
5.2 Pathological modifications of α-synuclein in proteasome-inhibited 
transgenic oligodendrocytes 
 
The aggregation of -synuclein into neuropathological lesions is accompanied by 
characteristic post-translational modifications, including phosphorylation at Ser129 
(Fujiwara et al., 2002) and oxidative nitration (Giasson et al., 2000).  Such pathological -
synuclein modifications were also prominently visualized in GCIs of MSA patients (Figure 
20) using antibodies against Ser129-phosphorylated -synuclein (Fujiwara et al., 2002) 
and oxidized -synuclein (Duda et al., 2002), respectively.  Likewise, some of the 
inclusions that developed in primary -synuclein transgenic oligodendrocytes exposed to 
proteasome inhibitors were also decorated with these diagnostic antibodies (Figure 20).  
Phosphorylated -synuclein and oxidized -synuclein were more restricted to inclusions 
compared to overall -synuclein staining with the 15G7 antibody, confirming the 
pathological nature of such modified -synuclein.   
The apparent oxidation of -synuclein protein that specifically became detectable after 
proteasome inhibition in -synuclein transgenic oligodendrocytes indicates that the 
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environment within these cells is oxidizing, consistent with the notion that UPS failure 
causes oxidative stress (Hyun et al., 2004; Lee et al., 2001c).  Oxidative nitration of 
proteins is evidenced by strong immunolabeling of cytosolic -synuclein inclusions with 
an antibody that recognizes 3-nitrotyrosine (3-NT) (Figure 20; insert). 
Oxygen radicals can damage not only proteins, but also lipids.  For example, 
polyunsaturated fatty acids are peroxidized by reactive oxygen species, and further 
oxidation leads to breaking of the acyl chain into toxic aldehyde metabolites.  A marker of 
such lipid peroxidation is 4-hydroxy-2-nonenal (HNE), which can be detected by specific 
antisera (Uchida, 2003).  Weak but significant immunostaining of HNE was observed in 
GCIs of human MSA patients as well as in the -synuclein inclusions of proteasome-
inhibited transgenic oligodendrocytes (Figure 20).  Thus, proteasome inhibition in -
synuclein transgenic oligodendrocytes appears to generate free radicals, which oxidize 
proteins and lipids like in human patients.   
-synuclein within aggregates has an “amyloid” structure that is rich in -pleated 
sheets (Conway et al., 2000a), which can be selectively stained with thiazole dyes such as 
thioflavin S.  Indeed, GCIs in postmortem tissue from MSA patients could be stained with 
thioflavin S (Figure 20) following the procedure described by (Schmidt et al., 2001).  In 
primary -synuclein transgenic oligodendrocytes challenged with proteasome inhibitors, 
only 1.7% ± 0.5% of small -synuclein aggregates, but 54% ± 3.2% of large -synuclein 
aggregates were positively stained with thioflavin S (Figure 20).  Thus, the peripheral 
small -synuclein aggregates were not rich in “amyloid” fibrils, a property that appears to 
be acquired as the aggreates converge into large perinuclear GCI-like structures. 
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Figure 20:  Sections from MSA brains and -synuclein transgenic oligodendrocytes challenged with 
epoxomicin were stained with antibodies against markers of pathological modifications and oxidative 
stress.  Both GCIs and inclusions in epoxomicin-treated oligodendrocytes were immunoreactive with 
antibodies against -synuclein phosphorylated at Ser129 and oxidized -synuclein.  Generalized protein 
oxidation in GCI-like inclusions was detected with antiserum against 3-nitrotyrosine (insert).  The 
presence of oxidized lipid in GCIs and -synuclein aggregates was revealed by 4-hydroxynonenal 
staining. The amyloid nature of aggregated -synuclein was revealed by thioflavin S staining (N-P), 
with the large perinuclear inclusions (loer left insert O) showing great similarities to GCIs (M).  Note 
that all markers tended to be confined to the perinuclear inclusions in the cell culture model.  Nuclei 
were counterstained with Hoechst dye (blue).  Scale bars, 20µm (A-L); 10µm (M-P).   
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To further establish the fibrillar nature of the -synuclein aggregates immunogold electron 
microscopy was performed on proteasome inhibitor treated transgenic oligodendrocytes. 
Immunogold-labeled -synuclein fibrils were found neither in primary eGFP-transgenic 
nor in -synuclein transgenic oligodendrocytes in the absence of proteasome inhibitor, or 
in epoxomicin-treated primary eGFP transgenic oligodendrocytes (not shown).  In contrast, 
electron-dense aggregates were detected in primary -synuclein transgenic 
oligodendrocytes challenged with epoxomicin (Figure 21).  Immunogold labeling depicted 
large granulo-filamentous structures.  These aggregates contained -synuclein-positive 
fibrils, which appeared as straight filaments with a diameter of 15-25nm (Figure 21), 
consistent with the reported diameters of -synuclein fibrils in GCIs (Gai et al., 2003; Tu 
et al., 1998). 
N
control epoxomicin treated  
Figure 21:  Pre-embedding immunogold labeling electron microscopy was performed on primary -
synuclein transgenic oligodendrocytes.  In the absence of proteasome inhibitor no immunogold-labeled 
-synuclein fibrils were found (left panel).  After treatment with epoxomicin, large aggregates formed 
in juxtaposed to indented nuclei (N).  The spherical inclusions contained autophagosomes (arrows) and 
lipid droplets (arrowheads).   Randomly arranged filaments associated with granular material were 
resolved at higher magnification.  The fibrils were decorated with anti--synuclein immunogold 
particles (right panel).  Scale bar, 10µm (mid panel).  
 
6 Cellular Consequences of -synuclein Aggregation for Affected 
Oligodendrocytes  
6.1 Sensitization of α-synuclein transgenic oligodendrocytes to proteasome 
inhibitor mediated apoptosis 
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Up-regulation of the apoptosis-related protein Bcl-2 and terminal deoxynucleotidyl 
transferase-mediated nick end-labeling evidenced apoptosis in MSA patient 
oligodendrocytes (Probst-Cousin et al., 1998).  Therefore I investigated if the formation of 
-synuclein inclusions in transgenic oligodendrocytes was accompanied by apoptosis.  
Light microscopical examination showed that proteasome-inhibited transgenic 
oligodendrocytes displayed altered morphologies with shortened processes, shrunken cell 
bodies, and condensed chromatin.  Electron microscopy of -synuclein oligodendrocytes 
treated for 24h with 10µM epoxomicin demonstrated apoptotic changes, including 
invagination and disruption of the nuclear membrane and chromatin condensation.  
Vacuolizations within the cytosol were frequently observed, most notably autophagic 
vacuoles with double or single membrane containing electron-dense granular material.  
Mitochondria accumulated around the -synuclein aggregates, as evidenced by 
cytochrome C immunofluorescence staining (Figure 22A) and electron microscopy (Figure 
22B; white arrows).  Most of the mitochondria appeared swollen, and -synuclein was 
often found to be associated with the outer mitochondrial membrane (Figure 22C), 
suggesting a direct involvement of -synuclein in oligodendrocyte apoptosis. 
It has been suggested that some toxic -synuclein folding intermediate might 
directly damage the mitochondria, potentially initiating an apoptotic cell death cascade 
(Hashimoto et al., 2003; Volles and Lansbury, 2003).  Swollen mitochondria will 
eventually rupture and release cytochrome C, which in turn activates an apoptotic cascade 
that activates caspase-3 (Jiang and Wang, 2004; Polster and Fiskum, 2004).  Indeed, 
immunostaining of activated caspase-3 was observed in epoxomicin-treated transgenic 
oligodendrocytes, particularly those with high levels of -synuclein accumulation (Figure 
RESULTS 
 
 82 
22D-F).  Consistent with the sequence of events during apoptosis, activation of caspase-3 
preceded chromatin condensation and the final breakdown of the cell. 
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Figure 22: (A-C)  The recruitment of mitochondria around the SYN aggregates was shown by 
immunostaining with cytochrome c antibody (A, green) and electron microscopy (B, white arrows).  
Scale bar, 5m. Anti--synuclein immunogold particles localized to the outer membrane of damaged 
mitochondria (C).  (D-F) The accumulation of -synuclein within the cytosol, prior the formation of 
microscopically visible -synuclein aggregates (D) parallels the activation of capsase-3 (E, F).  Scale 
bar, 20m. 
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Quantitative analysis revealed that, when challenged with increasing doses of epoxomicin, 
primary -synuclein transgenic oligodendrocytes were sensitized to caspase-3 activation 
(Figure 23A) and apoptotic chromatin condensation compared to eGFP transgenic 
oligodendrocytes.  When left untreated, about 8% of -synuclein- and eGFP-transgenic 
oligodendrocytes were positive for active caspase-3, reflecting spontaneous cell death.  
Proteasome inhibition with 0.1 epoxomicin resulted in caspase-3 activation in 33.8% ± 
2.1 of eGFP-overexpressing oligodendrocytes and 49.1% ± 0.7 of -synuclein 
overexpressing cells.  Hoechst staining revealed apoptotic morphology in about 35.3% ± 
1.1 of these -synuclein oligodendrocytes. 
 Because of the strong apoptosis-inducing effects of epoxomicin (Figure 23A), I 
studied the correlation between GCI formation and oligodendroglial apoptosis in LV-
SYN transduced cultures, in which inclusions form even in the absence of proteasome 
inhibitor.  Transduction with the control vectors LV-eGFP and LV-SYN activated an 
apoptotic cascade (as evidenced by active caspase-3 immunostaining) in 10-15% of the 
cells, most likely reflecting general toxicity of transduction of primary oligodendrocytes.  
Remarkably, a significantly greater proportion of the LV-SYN transduced 
oligodendrocytes showed activation of caspase-3 (Figure 23B).  Similar to 
oligodendrocytes isolated from transgenic (PLP)--synuclein mice, oligodendrocytes 
transduced with LV-SYN were sensitized almost two-fold to proteasomal inhibition, even 
beyond the significant toxicity medited by lentiviral overexpression alone (Figure 23B).   
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Figure 23: (A, B) Quantitative analysis depicts the dose-dependent activation of the apoptosis effector 
caspase-3 in primary oligodendrocytes.  Oligodendrocytes were scored as active caspase-3 
immunoreactive when the cytosol was intensely labeled.  The graphs show the primary stained with O4.  
Parallel transgenic eGFP and -synuclein cultures were exposed for 1 day to increasing concentrations 
of epoxomicin (A). Wild-type oligodendrocytes were transduced with LV-eGFP (black bars), LV-SYN 
(light bars), and LV-SYN (dark bars), and subsequently treated with 0µM or 10µM epoxomicin (B).  
Data are means +/- SEM from 3-5 independent experiments conducted in triplicate.  Student t test; 
*P<0.05; **P<0.001 compared to eGFP, ##P<0.001 compared to solvent control. 
 
 
7 Lentiviral Delivery of -Synuclein Suppresses the Formation of -
Synuclein Inclusions and Apoptosis in Proteasome-Inhibited 
Transgenic Oligodendrocytes 
 
Since -synuclein aggregation seems to parallel caspase 3 activation on my MSA model, I 
decided to investigate whether anti-aggregative gene therapy could reduce α-synuclein 
mediated cytotoxicity. 
-synuclein is not only incapable of forming pathological fibrils, but actually inhibits -
synuclein aggregation in vitro (Hashimoto et al., 2001; Park and Lansbury, 2003; Uversky 
et al., 2002). When (PDGF)--synuclein mice were crossbred with transgenic mice 
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expressing -synuclein throughout the brain, or when -synuclein was administered using 
lentiviral vectors, a significant reduction of the number of neuronal -synuclein inclusions 
was detected (Hashimoto et al., 2004; Hashimoto et al., 2001).  
In order to establish the anti-aggregative and cytoprotective properties of LV-
SYN for oligodendrocytes, differentiated primary -synuclein transgenic 
oligodendrocytes were transduced with LV-eGFP or LV--synuclein. After 2 days, cells 
were incubated for another 18h with 10 epoxomicin or control solvent.  15G7 
immunostaining analysis revealed that about 60% of the transgenic oligodendrocytes 
depicted cytosolic -synuclein aggregates when transduced with LV-eGFP lentiviral or left 
untransduced.  This percentage was decreased to 23.4 ± 4.7% when -synuclein transgenic 
oligodendrocytes were transduced with LV-SYN prior to the exposure to epoxomicin 
(Figure 24A). 
While less than 10% of control -synuclein oligodendrocytes were apoptotic, 
epoxomicin treatment increased this percentage to approximately 60%.  In contrast, LV-
SYN transduction decreased the number of oligodendrocytes with activated caspase-3 
down to 17.7 ± 3.8% (Figure 24B).  Given the close correlation between the percentage of 
oligodendrocytes bearing inclusions and activated caspase-3, and the rescue mediated by 
LV-SYN, GCI formation may be cytotoxic.  Furthermore, LV-SYN gene therapy could 
suppress oligodendrocyte pathology and possibly even putative oligodendrocyte 
dysfunction in MSA.  
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Figure 24: Primary (PLP)--synuclein transgenic oligodendrocyte cultures were incubated with no 
vector, LV-eGFP, and LV-SYN, as indicated.  After 2 days in culture, the cells were challenged or not 
(0µM) with 10µM epoxomicin for another day.  Then cells were fixed and stained with anti-SYN (A) 
and activated caspase-3 (B).  Data are means +/- SEM from 3-5 independent experiments conducted in 
triplicate.  Student t test; *P<0.05; **P<0.001. 
 
 
8 Molecular Mechanisms Involved in Oligodendroglial Cell Death  
8.1 Both the intrinsic (mitochondrial) and the extrinsic (death receptor) 
pathways are involved in α-synuclein-sensitized oligodendrocyte 
apoptosis  
 
To substantiate the causal role of caspases in the apoptosis of epoxomicin-treated -
synuclein oligodendrocytes, primary transgenic oligodendrocytes were pre-incubated for 
20min with 100 of the broad-spectrum caspase inhibitor z-VAD-fmk and evaluated the 
percentage of apoptosis induced by 10 epoxomicin.  While 52.5% ± 5.5 of the 
transgenic -synuclein oligodendrocytes displayed loss of cell processes and apoptotic 
chromatin condensation visualized by Hoechst staining after 24h proteasome inhibition, 
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pan-caspase inhibition strongly protected transgenic oligodendrocytes from cell death, 
bringing the percentage of apoptotic cells down to basal levels (Figure 25).  
To further dissect the apoptosis pathways, specific inhibitors z-DEVD-fmk, z-
IETD-fmk and z-LEHD-fmk against respectively caspase-3, caspase-8 and caspase-9 were 
employed.  Consistent with its role as an executioner of apoptosis, caspase-3 was found to 
be critical to mediate apoptosis in epoxomicin-treated -synuclein transgenic 
oligodendrocytes, because caspase-3 inhibition strongly suppressed apoptosis under these 
conditions (Figure 25).  Inhibition of caspase-9 significantly reduced apoptosis, consistent 
with a mitochondrial apoptosis pathway.  Unexpectedly, the percentage of cell death was 
dramatically decreased to about 3% in the presence of a caspase-8 inhibitor (Figure 25).  
Caspase-8 is a pivotal mediator of death receptor-triggered apoptosis (Thorburn, 2004).  
Thus, in addition to mitochondrial apoptosis pathways, ligand-induced cell death pathways 
might be of relevance to -synuclein-sensitized oligodendrocyte death. 
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Figure 25:  After 2 weeks in culture, primary -synuclein transgenic oligodendrocytes were treated 
with the broad spectrum caspase inhibitor z-VAD-fmk or specific inhibitors z-DEVD-fmk, z-IETD-fmk 
and z-LEHD-fmk against caspases-3, -8 and -9.  Control cultures were returned to BS medium in the 
absence of caspase inhibitors.  After 20min, 10M epoxomicin (or BS medium for control cultures) was 
added to the wells for a further 24h.  Cells were immunostained for -synuclein, active caspase-3 and 
counterstained with Hoechst nuclear dye.  Quantitative analysis revealed that proteasome inhibition and 
subsequent -synuclein accumulation elicited caspase-3 activation (I, **) and cell death (J, **), which 
were significantly blocked by caspase 1, 3 and 8 inhibitors (##).  Data are means +/- SEM from 5 
independent experiments conducted in triplicate.  Student t test; **P<0.001 compared to control; 
##P<0.001 compared to epoxomicin alone. 
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8.2 Expression of α-synuclein in oligodendrocytes specifically sensitizes to 
Fas-mediated apoptosis via Fas upregulation 
 
The surprising efficacy of caspase-8 inhibitors to suppress -synuclein-sensitized 
apoptosis in primary oligodendrocytes prompted me to systematically investigate the 
effects of death receptor ligands on transgenic oligodendrocytes.  Differentiated primary 
oligodendrocyte cultures derived from eGFP and -synuclein transgenic mice were treated 
for 24h with nerve growth factor (NGF, which can exert cytotoxicity via the p75 
neurotrophin receptor), the pro-inflammatory tumor necrosis factor- (TNF-, which 
activates caspase-8 via recruitment of the TNF receptor associated death domain protein), 
TNF-Related Aptosis-Inducing Ligand (TRAIL) and Fas ligand (stimulating apoptosis 
through the recruitment of Fas associated death domain proteins).  NGF and TNF- 
treatment had no significant cytotoxic effect under these conditions, neither in primary 
eGFP oligodendrocytes nor in primary -synuclein transgenic oligodendrocytes (Figure 
26).  TRAIL caused a moderate increase in the percentage of oligodendrocytes with 
apoptotic nuclei, especially in the -synuclein transgenic cultures, but the cytotoxic effect 
of TRAIL was much lower compared to, e.g. epoxomicin treatment (Figure 26).  
In contrast to the ineffective, soluble form of Fas ligand (Schneider et al., 1998), 
which did not efficiently stimulate apoptosis under these conditions, the active, membrane-
bound form of Fas ligand stimulated apoptosis in 46.7 ± 5.24% of eGFP transgenic 
oligodendrocytes.  -synuclein transgenic oligodendrocytes were significantly sensitized to 
Fas-mediated apoptosis, with 79.3 ± 8.3% cells bearing apoptotic nuclei (Figure 26).  The 
apoptotic potency of membrane-bound Fas ligand was completely blocked by neutralizing 
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with Fas antibody (Figure 26A, B), corroborating the specificity of -synuclein 
sensitization to Fas-mediated apoptosis in cultured oligodendrocytes. 
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Figure 26:  (A)  eGFP and -synuclein oligodendrocytes were treated 24h with DMSO, epoxomicin, 
NGF, TNF, TRAIL, soluble Fas ligand (sFas), membrane-bound Fas ligand (mFas) or preincubated for 
30min with Fas blocking antibody and challenged with mFas.  Cells were then fixed, labeled with O4 
and propidium iodide.  mFas ligand treatment induced Fas trimerization and oligodendrocyte cell death, 
-synuclein oligodendrocytes being significantly (*) more sensitive to Fas mediated cell death than 
eGFP oligodendrocytes.  Fas ligand mediated cell death was reverted by preincubation with Fas-
blocking antibody.  Data represent mean percentage ± S.E.M of total transgenic oligodendrocytes from 
3 independent experiments.  Student t test *P<0.05, **P<0.001, ***P<0.0001 compared to untreated 
cultures; #P<0.005, ##P<0.001 compared to eGFP transgenic cultures exposed to the same challenge.  
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(B)  Phase contrast imaging shows that pretreatment with Fas blocking antibody preserved 
oligodendrocyte morphology and prevented process loss. 
 
The simplest mechanism by which oligodendrocytes would be sensitized to the 
apoptotic effects of Fas ligand is up-regulation of Fas itself.  I determine by biochemical 
analysis Fas levels in wild-type and -synuclein transgenic oligodendrocytes and found a 
great upregulation in a-synuclein transgenic cells (figure 27). 
tubulin
Fas
con a-syn
 
Figure 27:  Primary wild-type and -synuclein transgenic oligodendrocytes were cultured for 2 weeks 
and lysed.  30g of cell lysates were electrophoresed and Western blotted, and probed with monoclonal 
Fas antibody. 
 
8.3 Fas upregulation is observed in MSA 
 
To investigate if Fas upregulation and Fas-sensitization observed in transgenic -synuclein 
oligodendrocytes are relevant to MSA, I analyzed the expression of Fas in post-mortem 
human tissue.  Remarkably, Western blots prepared from cerebellar white matter lysates of 
MSA patients contained more Fas than control samples (Figure 28).  To prove that -
synuclein aggregation (GCI formation) specifically up-regulates the Fas receptor on 
oligodendrocytes, double-label immunostaining using antibodies against -synuclein and 
Fas was performed on cerebellar white matter from human MSA brain.  
Immunohistochemistry confirmed that Fas was upregulated in MSA, and identified 
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oligodendrocytes as the cell type that induced the pro-apoptotic Fas receptor.  In contrast to 
control samples, which were generally devoid of Fas, MSA white matter showed Fas 
receptors specifically associated with GCIs (Figure 28).  Roughly 10-15% of GCI-bearing 
oligodendrocytes identified by -synuclein staining were immunopositive for Fas.  The 
punctuated pattern of Fas immunostaining on pathological oligodendrocytes is similar to 
the punctuated Fas staining of oligodendrocytes in multiple sclerosis lesions (D'Souza et 
al., 1996).  It is tempting to speculate that this reflects Fas receptor clustering, which 
activates the death domain to induce apoptosis.  In addition to oligodendroglial (GCI) 
pathology, MSA is also characterized -synucleinopathy in neurons (NNIs).  -synuclein 
and Fas double-immunostained sections of MSA patients demonstrated that NNI-bearing 
neurons were strongly Fas-immunoreactive (Figure 28E).  Thus, induction of the pro-
apoptotic Fas receptor by -synucleinaggregation is not restricted to oligodendrocyctes, 
but is also observed on neurons.  It would be therefore of greatest importance to investigate 
whether LB positive neurons in PD and DLB also induce Fas, to determine whether Fas is 
a general key component of cytotoxicity in -synucleinopathies 
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Figure 28:  (A)  Western blot prepared from lysates of cerebellar white matter of controls (lanes 1, 2) 
and MSA patients (lanes 3, 4) were sequentially probed with anti-Fas (upper panel) and anti-actin 
(lower panel) to confirm equal loading.  (B-C)  Immunohistochemical analysis of cerebellar white 
matter in human MSA brain reveals Fas-positive microglial cells and astrocytes (arrowheads) and 
staining of cells, which resemble GCI-bearin goligodendrocytes (arrow). (B)  Higher magnification of 
A
B
A 
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GCI-bearing oligodendrocytes.  (D-E)  Double-label immunofluorescence staining for Fas and SYN of 
cerebellar white matter in human MSA brain reveals Fas-expression (green) co-localizes to a subset of 
oligodendrocytes with SYN-positive GCIs (red).  In addition, strong Fas labeling was observed in 
single neurons with nuclear SYN-positive inclusions in the pons (E).  Scale bar corresponds to 50m 
(B) and 12.5m (C-E). 
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Chapter 5:  Discussion 
 
Recently, the dual roles of -synuclein in neuroprotection and neurotoxicity were 
described (Chandra et al., 2005; da Costa et al., 2003).  However, there is no clear picture 
of its biological activity, and the primary pathophysiological function of -synuclein 
remains to be better defined.  -synuclein is genetically and pathologically linked to PD 
(Pfeiffer and Wagner, 1994; Polymeropoulos et al., 1997; Spillantini et al., 1997) and 
neurodegenerative disorders characterized by the presence of pathological brain inclusions 
that predominantly consist of filamentous, aggregated -synuclein protein are collectively 
referred to as -synucleinopathies (Spillantini et al., 1998a).  While neurons are 
predominantly affected by pathological misfolding of -synuclein in PD and DLB, 
oligodendroglial cytoplasmic -synuclein inclusions comprise the hallmark for MSA.   
 
1) Adverse effects of -synuclein on oligodendrocyte viability 
The primary
 
importance of oligodendroglial dysfunction in the neurodegenerative
 
process 
of MSA may also be supported by the observation that
 
the distribution of cells undergoing 
apoptosis is comparable with that of the GCI
 
pathology and also that apoptosis primarily 
affects oligodendroglial
 
cells in MSA (Probst-Cousin et al., 1998). 
Many toxin animal models of MSA have been developed over the years.  Two of the most 
widely used toxin models to mimic the symptoms and striatonigral degeneration of MSA 
involve chemical administration to rodents of either MPTP (Ghorayeb et al., 2002) or 3-
nitropropionic acid (Fernagut et al., 2002) (single toxin-double lesion models) or 6-
hydroxydopamine and quinolic acid (double toxin-double lesion model) (Puschban et al., 
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2000).  Although both of these models are believed to induce MSA-like pathology and/or 
phenotype through oxidative mechanisms (Stefanova et al., 2005c), 
recapitulate the presence of -synuclein inclusions.   
Both causes and effects of -synuclein aggregation in MSA remain enigmatic as 
oligodendrocytes express undetectable levels of α-synuclein in the mature brain (Solano et 
al., 2000b).  Thus, ectopic expression of α-synuclein could be causally linked to MSA 
pathology.  Therefore, to more thoroughly and realistically study MSA in animals, 
transgenic mouse models were created.  (PLP)--synuclein mice showed an accumulation 
of hyperphosphorylated -synuclein within oligodendrocyte cell bodies (Kahle et al., 
2002b).  The pathologically phosphorylated transgenic -synuclein was found to be 
detergent-insoluble.  However, the transgenic expression of -synuclein in mouse brain 
under the PLP promoter leads only to an early pathology as -synuclein did not further 
mature to true “amyloid” fibrils.  Possibly the (PLP) oligodendrocyte specific promoter 
employed did not mediate sufficiently high expression to generate a phenotype.  
Alternatively, oligodendrocytes may have a great capacity to suppress -synuclein 
misfolding, either because of an abundance of small heat shock proteins (such as B-
crystallin) (Neri et al., 1997) or additional genetic or environmental risk factors may 
exacerbate oligodendroglial MSA pathology.   
One such risk factor might be exposure to environmental toxins.  In fact, the (PLP)--
synuclein mice were sensitized to 3-nitropropionic acid, a mitochondrial toxin and resulted 
in MSA-like features including complex locomotor
 
impairment and neuropathological 
changes such as striatonigral degeneration, olivopontocerebellar
 
neuronal loss, astrogliosis, 
and microglial activation, along
 
with the GCI-like pathology.  Environmental toxins 
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exacerbate MSA pathology in the mouse (Stefanova et al., 2005b).  These results support 
the idea of a “multi-hit” scheme for MSA pathogenesis in which mitochondrial dysfunction 
may play a role.  Another pro-aggregative risk factor may be concomitant taupathy.  When 
a (CNP) promoter was used employed to express human -synuclein in transgenic mouse 
oligodendrocytes, no particular pathology and phenotype were observed in the young 
adults.  When these animals were crossbred with mice that express (P301L)tau in 
oligodendrocytes, a subset of bigenic oligodendrocytes developed a fibrillar -synuclein 
pathology, as demonstrated by thioflavin S staining (Giasson et al., 2003a).  Such amyloid 
formation coincided with a limb phenotype.  It is tempting to speculate that in 
oligodendrocyte cytosol, -synuclein and tau synergistically form individual fibrils, as was 
shown in vitro (Giasson et al., 2003a).  However, it has not been reported if demyelination 
and/or neurodegeneration occur in specific brain regions of these mice, and what molecular 
mechanisms contribute to the phenotype of (CNP)--synuclein x tau mice.   
Earlier this year, a more human disease-like transgenic mouse was created by Yazawa et 
al.  Human -synuclein is expressed in oligodendrocytes under the control of the (CNP) 
oligodendrocyte-specific promoter (Yazawa et al., 2005).  These mice exhibit some age-
dependent neurodegeneration, and -synuclein-positive aggregates are present in 
oligodendrocytes, supporting the view that -synuclein pathology in oligodendrocytes may 
cause neurodegeneration (Yazawa et al., 2005).  However, these -synuclein inclusions are 
not thioflavin S positive as they are in the human diseased brain.  The CNP-a-synuclein 
mice lack neuronal cell loss in many brain regions commonly affected in MSA, such as 
substantia nigra. These studies indicate that α-synuclein overexpression alone is not 
adequate for truly replicating the complexities of MSA pathology and highlight the 
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importance of both genetic predisposition (ectopic -synuclein expression in 
oligodendrocytes) and epigenetic factors (environmental toxins, aging) causes in MSA 
(Stefanova et al., 2005). Future studies will likely examine whether substantia nigra and 
other brain regions are more vulnerable to toxic insults such as mitochondrial, as was 
recently demonstrated in mice that overexpress α-synuclein in oligodendroglia via the PLP 
promoter (Stefanova et al., 2005).  
By developing a transgenic mouse that overexpresses human α-synuclein in 
oligodendrocytes via the oligodendrocyte specific MBP promoter, Shults and colleagues 
(Shults et al., 2005) have effectively recapitulated several of the key functional and 
neuropathological features of MSA. Not only do mice exhibit GCI formation in 
oligodendrocytes, they also display signs of neurodegeneration.  The sequence of these 
events suggests that oligodendroglial abnormalities are the primary cause of MSA and 
drive neurodegeneration.  This work further establishes a critical role for α-synuclein in 
MSA pathology and neurodegeneration. It supports the prediction that an overabundance 
of α-synuclein in oligodendroglia is a key event in MSA pathogenesis.  
 
When I started this work, it existed only the (PLP)--synuclein genetic model, which 
failed to fully recapitulate MSA pathology (Kahle et al., 2002b) and the consequences of 
-synuclein expression, as well as the molecular mechanisms leading to its aggregation, 
had never been studied in primary oligodendrocyte cultures.  The goal of my PhD research 
project was to gain insight into the mechanisms by which -synuclein aggregation causes 
oligodendroglial pathology and how this process can be modulated.  I focused mainly on a 
biochemical and cell biological analysis of -synuclein fibrillogenesis and toxicity in 
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oligodendrocyte.  For this purpose, I developed a cellular model of oligodendroglial MSA 
pathology by isolating oligodendrocyte progenitors from transgenic (PLP)--synuclein 
mice. 
 
Immunostaining of primary transgenic oligodendrocyte cultures with the human specific 
monoclonal 15G7 antibody revealed that the transgenic -synuclein is diffusely distributed 
throughtout the cytosol.  Possibly, (PLP) -synuclein expression in primary 
oligodendrocytes under basal conditions was not robust enough to induce -synclein 
aggregation and oligodendrocyte degeneration, similar to what was documented for 
transgenic (PLP)--synuclein mice in vivo (Kahle et al., 2002b).  Proteasome inhibition of 
(PLP)--synuclein transgenic oligodendrocytes increased cytosolic -synuclein 
concentrations and induced -synuclein aggregation.  Initially, small -synuclein 
aggregates formed and then appeared to coalesce and mature to a single large perinuclear 
GCI-like inclusion, similar findings were reported in an adenoviral COS-7 cell culture 
model (Lee and Lee, 2002).  Special emphasis should be placed on the process of 
formation of the large inclusions form. In fact, it remains unknown whether this maturation 
follows an aggresome-like mechanism by which small aggregates would be transported to 
the microtubule organizing center (Johnston et al., 1998).  Thus, interfering with the 
microtubular transport system could help elucidating the maturation mode of the large -
synuclein aggregates.  The tubulin depolymerizing drug nocodazole is widely used to block 
aggresome formation (Lee and Lee, 2002), but its use in primary (PLP)--synuclein 
oligodendrocytes was hampered by its toxicity.  Thus, it remains to be shown if the 
formation of GCIs involve aggresomal mechanisms. 
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The use of proteasome inhibitors to induce MSA-like pathology raises the issue of 
potential artifacts due to general protein turnover impairment by proteasome inhibition and 
makes it difficult to determine whether high -synuclein levels could be sufficient to 
induce its aggregation.  An alternative approach to highly express -synuclein in primary 
oligodendrocytes cultures is to transduce wild-type oligodendrocytes with lentivirus 
harboring -synuclein constructs.  By transducing wild-type mouse oligodendrocytes with 
lentiviral vectors harboring the aggregation-prone -synuclein, the non-amyloidogenic -
synuclein, and control eGFP, high-level protein expression were achieved.  Unlike eGFP 
and -synuclein, which evenly distributed throughout oligodendrocytes, -synuclein often 
formed perinuclear inclusions, reminiscent of -synuclein staining in MSA patients 
(Lantos, 1998).  In summary, my data provides evidence that -synuclein, when expressed 
at sufficiently high concentrations, may spontaneously form GCI-like aggregates.  
 
The nature of the large -synuclein aggregates was characterized using established 
markers of GCI pathology.  Immunostaining with antibodies against ubiquitin revealed that 
-synuclein inclusions were positive ubiquitin, a well known GCI marker (Kato et al., 
1991).  Finally, the specific accumulation of strictly pathologically phosphorylated and 
oxidized -synuclein was shown by immunofluorescence with a specific antibody raised 
against phosphorylated serine 129 and nitrated -synuclein (Duda et al., 2000; Giasson et 
al., 2000; Fujiwara et al., 2002). 
The granulo-filamentous appearance of electron-dense inclusions is typical for GCIs (Kato 
et al., 1991), and these fibrils are labeled with anti--synuclein immunogold particles 
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(Arima et al., 1998; Spillantini et al., 1998a).  The fibrillar “amyloid” conformation of 
aggregated -synuclein in my models were confirmed by thioflavin S staining and the 
presence of immunogold labeled -synuclein fibrils in the inclusions.   
Detergent-resistant -synuclein is a biochemical marker of MSA autopsy samples and 
(PLP)--synuclein transgenic mice (Kahle et al., 2002b).  Conversion of detergent-
insoluble -synuclein to fibrillar “amyloid” appears to be age- and gene dependent, at least 
in neuronal -synucleinopathy mouse models (Giasson et al., 2002; Lee et al., 2002; 
Neumann et al., 2002).  Biochemical experiments using the relatively mild urea extraction 
protocol was performed on primary transgenic -synuclein and eGFP oligodendrocyte 
cultures and revealed pathological insolubility of a significant fraction of the transgenic -
synuclein after proteasome inhibition, in contrast to eGFP protein.  The characteristic 
ubiquitination of -synucleinopathy inclusions were also visualized in my model by 
Western probing extracts from transgenic oligodendrocytes with antibodies against 
ubiquitin. 
 
Once the primary culture models of oligodendroglial -synuclein fibrillization were fully 
characterized, the adverse effects of -synuclein on oligodendrocyte viability were studied.  
These pathological deposits evidently impose a challenge to the oligodendrocytes, and it is 
reasonable to assume that the observed co-localization of chaperone proteins in the -
synuclein inclusions formed in the epoxomicin-treated transgenic oligodendrocytes as well 
as in GCIs of human patients reflects a defense mechanism against protein misfolding.  
Hsp70 has been previously shown to suppress -synuclein aggregation in cell culture 
(McLean et al., 2002) and in neurons of transgenic mice (Klucken et al., 2004), and 
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neurotoxicity in transgenic Drosophila (Auluck et al., 2002).  The finding of Hsp70 and its 
co-chaperone Hsp40 in -synuclein inclusions formed in oligodendrocyte cultures suggests 
that these molecular chaperones are recruited to these pathological structures.  
Furthermore, B-crystallin, a reference marker of GCIs, was also present in transgenic 
oligodendrocyte -synuclein inclusions, thereby providing evidence for the recruitment of 
this chaperone protein to oligodendroglial -synuclein inclusions, as suggested in a recent 
report using C6 glioma cells (Pountney et al., 2005).  The small heat shock protein B-
crystallin is thought to be a major chaperone in oligodendrocytes, which is instrumental to 
maintain microtubular integrity of these cells (Goldbaum and Richter-Landsberg, 2004).  
However, when proteolytic stress exceeds the chaperone capacity, disturbances of the 
microtubular network may accrue.  It is possible that p25and 14-3-3, both of which have 
been found in GCIs (Kawamoto et al., 2002; Kovacs et al., 2004) and in proteasome 
inhibitor treated -synuclein transgenic oligodendrocytes, reflect such microtubular 
damage in a manner that remains to be fully established.   
 
-synuclein fibrillization within oligodendrocytes is cytotoxic as shown by the 
deterioration of the ramified morphology that characterizes well-differentiated 
oligodendrocytes.  How the formation of -synuclein aggregates is mechanistically linked 
to cellular toxicity is a matter of intense debate (Wanker, 2000).  Several reports presented 
evidence that aggregate formation may even be a protective mechanism (Tanaka et al., 
2004; Taylor et al., 2003).  Mainly two, non-exclusive, ideas have been put forward for 
how -synuclein aggregation may cause cellular dysfunction.  In one model, aggregated -
synuclein proteins are thought to engage the ubiquitin proteasome system in a non-
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productive manner, causing a partial inhibition of proteasome-dependent cell regulation 
(Bence et al., 2001; Kovacs et al., 2004; Snyder et al., 2003).  In the other model, cell 
toxicity results from the ability of the aggregates to sequester factors essential to cell 
viability, such as components of the protein quality control system.  The underlying 
mechanisms of both proposed toxicity mechanisms and their contribution to the pathology 
of MSA remain to be elucidated.  Inhibition of the proteasome system upon -synuclein 
expression was observed in -synuclein transgenic oligodendrocytes compared to eGFP 
oligodendrocytes.  The impairment of the proteasome system observed in culture was not 
sufficient to induce -synuclein aggregation but may nevertheless be of pathomechanistic 
significance, considering the long duration of the disease and the postmitotic nature of 
oligodendroglial cells.  Preliminary experiments done on MSA brain samples showed a 
great decrease of the chymotryptic activity in patients compared to controls, supporting the 
involvement of the ubiquitin proteasome system in MSA pathogenesis.  The models I 
developed should prove useful to test whether -synuclein aggregation is likely a cause 
leading to inhibition of the proteasome degradation.  The lentiviral -synuclein system 
would serve to provide insight into -synuclein toxicity mechanisms that affect ubiquitin-
proteasome function. 
2) Molecular mechanisms of oligodendroglial degeneration 
No matter how the apparent critical concentration for -synuclein fibril formation is 
reached (accumulation of transgenic -synuclein after proteasome inhibition or high-level 
over-expression with lentiviral vectors), oligodendrocytes are sensitized to apoptotic 
stimuli.  In my primary oligodendrocyte culture models of MSA, -synuclein fibrillization 
was accompanied by activation of caspase-3 and chromatin condensation visualized with 
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Hoechst nuclear staining.  Two main caspase activation pathways, receptor-mediated 
sequential activation of caspase-8 and cytochrome-c dependent nonreceptor mediated 
caspase-9 activation, are known to be involved in caspase 3-induced apoptosis (Lavrik et 
al., 2005b).  Ultrastructural examination of the dying oligodendrocytes revealed 
mitochondrial damage, and anti--synuclein immunogold particles were found in the 
vicinity of damaged mitochondria (Figure 22C).  Thus, I expected the intrinsic 
(mitochondrial) apoptosis pathway to be responsible for -synuclein-sensitized 
oligodendrocyte death.  To determine which type of caspase pathway functions in α-
synuclein induced apoptosis, I dissected the molecular pathways of apoptosis in this system 
using specific caspase inhibitors.  Interestingly, inhibition of caspase-9, the major effector 
of the mitochondrial apoptosis cascade, was less efficient blocking cytotoxicity in my 
model than inhibition of caspase-8 (Figure 25), which is known to be activated by cell 
death receptors.  However, additional experiments to confirm that caspase-9 and caspase-8 
inhibitors work equally well should be conducted. 
I investigated in greater molecular details how -synuclein inclusions trigger the apoptotic 
cascade via the extrinsic apoptosis pathway coupled to caspase-8 in -synuclein-
expressing oligodendrocytes.  In a systematic analysis of death receptor agonists, Fas 
ligand was the most efficient apoptosis inducer in primary oligodendrocyte cultures.  α-
synuclein-induced caspase-8 activation suggests the possible involvements of Fas and 
FasL, which act together in receptor-mediated apoptosis (Ferrer et al., 2000).  Importantly, 
-synuclein expression significantly sensitized oligodendrocytes to Fas-mediated 
apoptosis, when compared to eGFP transgenic oligodendrocytes (Figure 26A).  
Oligodendrocytes can express Fas on their membrane surface under pathological 
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conditions (D'Souza et al., 1996; Elovaara et al., 1999).  The involvement of Fas in α-
synuclein toxicity was confirmed by the elevated levels of Fas in cultured α-synuclein 
transgenic oligodendrocytes and in cerebellar white matter of MSA patients.  These data 
suggests that overexpressed α-synuclein up-regulates membranous Fas expression.   
 
The Fas/Fas ligand (FasL) system is believed to contribute to the suppression of 
inflammatory processes in the healthy brain (Choi and Benveniste, 2004).  Normally only 
few peripheral T lymphocytes invade the brain.  These are stringently controlled by a 
number of immunosuppressants, among them FasL.  In the case of multiple sclerosis, 
however, a strong auto-inflammatory reaction to myelin occurs, and the oligodendrocytes 
become a target of Fas-mediated apoptosis (D'Souza et al., 1996).  In the present study I 
provide evidence that Fas not only participates in the acute autoimmune damage of 
oligodendrocytes in multiple sclerosis lesions, but also occurs in the chronic disease MSA.  
The observed up-regulation of the pro-apoptotic Fas receptor -synuclein transgenic 
primary oligodendrocyte cultures, and in cerebellar white matter, one of the most severely 
affected brain regions of MSA patients, could enhance the vulnerability of 
oligodendrocytes (27A and 28).  Interestingly, transfection of -synuclein into IM-9 
myeloma cells has been recently reported to induce the Fas gene and increase Fas 
expression on the cell surface (Kim et al., 2004).  Additional biochemical and 
histochemical studies are warranted to elucidate the intracellular cascade of events 
triggered by -synuclein and mediating Fas induction in this disorder showing slow 
progression over many years.  For example, histochemical co-localization studies in MSA 
patients may provide information regarding the coupling between Fas expression and 
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activation of the extrinsic pathway, as evidenced by caspase-8 cleavage and Bid truncation 
(Lavrik et al., 2005a).   
 
Collectively, the results of this dissertation suggest that -synuclein overexpression in 
oligodendrocytes influences the aggregation of -synuclein protein, alter the conformation 
of -synuclein protein, and promote the stability of -synuclein fibrils, which are all 
relevant to the pathogenesis of MSA.  These data provide extensive evidence and support 
for the role and implication of -synuclein protein in the pathogenesis of MSA and may 
hopefully aid in the development of therapies for MSA patients and patients of 
synucleinopathies in addition to the creation of prophylactic treatments and remedies for 
the worldwide population that is at risk of developing this disorder.  Figure 29 summarizes 
the data collected from Chapters 4 in the attempt to understand the mechanism of -
synuclein fibrillogenesis and its consequences on glial pathology.  Increased expression of 
-synuclein protein most likely leads to altered function, structure, and conformation, 
which may also promote the dysfunction of the chaperone and ubiquitin-proteasome 
system, as described in the introduction.  The generation of misfolded, aggregated -
synuclein protein may obstruct cellular trafficking, disrupt cell morphology and 
homeostasis, and interfere with other cellular functions, which all may lead ultimately to 
cell death.  Further understanding of the correlation between α-synuclein levels and Fas 
upregulation/apoptosis will provide an insight into the molecular basis of the disease.   
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Figure 29:  Proposed model for the implications of -synuclein expression on the pathogenesis of MSA.  
Monomeric -synuclein naturally undergoes conformational and structural changes from random coil to -
pleated sheet and to small oligomers.  Chaperone proteins may aid in refolding these oligomers back to 
monomers.  Otherwise, the small oligomers or protofibrils might become ubiquitinated and targeted for 
proteasome degradation.  However, under pathological conditions if the small oligomers become polymeric 
and form protein aggregates, they will form GCIs and will not be degraded by the proteasome.  Furthermore, 
-synuclein is involved in apoptosis mechanism.  -synuclein expression also up-regulates membranous Fas 
expression which then sensitizes to caspase-8 activation. 
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3) Prophylactic approaches againt MSA 
The present study provides evidence that the α-synuclein may be one of the primary causes 
of MSA pathology and offers new targets for pharmacotherapeutic intervention.   
These results suggest that -synuclein pathology precedes disease phenotype, as Fas 
upregulation precedes -synuclein aggregation, therefore confirming the importance of 
disease detection before the onset of symptoms.  Antagonizing the -synuclein-Fas 
pathway could be tested in the (CNP)--synuclein mice, which show neurodegeneration 
even in the absence of amyloid-like GCI formation.  If Fas immunotherapy prevents 
neurodegeneration in these mice, it may offer opportunities for therapeutic approaches to 
MSA.   
 
A causal relationship of -synuclein aggregation and cytotoxicity can be derived from the 
finding that LV--synuclein prevents -synuclein aggregation and oligodendrocyte death 
to the same extent.  Although it remains to be rigorously proven if it is the visible GCI or 
some partially folded -synuclein “protofibrils” that kill oligodendrocytes, the beneficial 
effects of LV--synuclein on cultured oligodendrocytes open a possibility to treat 
oligodendroglial pathology.  It will be interesting to test if -synuclein-based suppression 
of GCI formation maintains the functions of oligodendrocytes (myelination, ion 
homeostasis) and neurodegeneration in transgenic mouse models of MSA (Kahle et al., 
2002; Yazawa et al., 2005).  The mechanisms by which -synuclein suppresses -
synuclein aggregation and toxicity were not defined in my thesis.  Further experiments 
would be needed to determine at what stage of the -synuclein toxicity pathway -
synuclein interferes.  Additionally, it would be necessary to clarify how -synuclein 
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interferes with the aggregation and cell toxicity processes, protecting oligodendrocytes 
against the detrimental effects of -synuclein accumulation.  In fact it remains unclear 
whether -synuclein exerts its protective function by physically interacting with -
synuclein and prevent the conformational changes leading to the formation of -pleated 
sheets (Hashimoto et al., 2001).  Alternatively, -synuclein may mediate its protective 
function by regulating pro-survival and apoptotic pathways.  Hashimoto et al., reported -
synuclein may directly interact with Akt, suggesting that this signaling pathway could be a 
potential therapeutic target for neurological conditions associated with parkinsonism and 
-synuclein aggregation (Hashimoto et al., 2004).  It was also shown that -synuclein 
triggers drastic reduction of p53 expression and transcriptional activity (da Costa et al., 
2003). 
β-Synuclein might function to ameliorate the proteasomal inhibition caused by aggregated 
α-synuclein and thereby limit proteasomal inhibition.  A previous study by Snyder et al., 
suggests that although β-synuclein has no direct effect on proteasomal activity, β-synuclein 
is able to modulate α-synuclein binding to the proteasome and thereby antagonizes the 
inhibition of the proteasome by aggregated α-synuclein (Snyder et al., 2004).  Altogether 
these data supports the use of β-synuclein or β-synuclein derived peptides for treatments of 
MSA and other synucleinopathies. 
 
Molecular chaperones of the Hsp70/Hsp40 family block the formation of amyloid-like 
fibrils in a cell culture model of Huntington‟s disease (Klucken et al., 2004; Schaffar et al., 
2004).  Interestingly, increased expression of molecular chaperones of the Hsp70/Hsp40 
system has been shown to suppress the neurotoxicity of -synuclein proteins (Auluck et 
DISCUSSION 
 
 110
al., 2005; Dedmon et al., 2005).  It would be of great interest to examine the effects of 
molecular chaperones on -synuclein aggregation in my cell culture models.  In order to 
study how Hsp70 can modulate -synuclein aggregation, -synuclein oligodendrocytes 
could be transduced with lentiviral vector coding for Hsp70, and the number of -
synuclein inclusions could be scored.  Along the same lines, stimulation of the stress 
response by a geldanamycin, a naturally occurring benzoquinone ansamycin that induces 
Hsp70, may prevent and/or revert -synuclein aggregation and toxicity in 
oligodendrocytes as it was previously shown in Drosophila (Auluck et al., 2005). 
 
 
4) Benefits and limitations of the in vitro models of MSA 
The primary oligodendrocyte culture models of MSA developed in this study are a unique 
tool to investigate in great details the molecular mechanisms of -synuclein aggregation 
and oligodendroglial death in MSA.  Furthermore, the cellular accessibility and 
microenvironmental control they offer are a big advantage to identify potential therapeutic 
compounds in MSA.  It was shown in this study that when -synuclein is in direct contact 
with oligodendrocytesit prevents -synuclein aggregation and toxicity; however, the 
effects seen in vitro must be confirmed or substianted in animal models and patients.  In 
fact, the lack of a blood-brain barrier in culture, a major factor in determining a chemical's 
access to the brain, limit the extrapolation of this result to the in vivo condition.   
Primary oligodendrocytes are isolated from normal in vivo homeostatic mechanisms.  
Refining these models by co-culturing primary neurons and -synuclein overexpressing 
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oligodendrocytes, would not only restore the synergistic interaction between all cell types 
present in the CNS but would also enable us to analyse oligodendrocyte dysfunction and 
myelination deficiencies in -synuclein oligodendrocytes and to assess neurodegeneration 
observed in the patients.   
 
MSA is a movement disorder, and animal models of MSA which combine authentic 
oligodendroglial and neuronal pathology with neurological dysfuntion would prove 
extremely useful to investigate the causal relationship between locomotor disorders and -
synuclein expression.  Along with CNP-α-synuclein mice (Yazawa et al., 2005), the MBP-α-
synuclein mice (Shults et al., 2005) provide the means to examine the potential downstream effects 
of α-synuclein overabundance in oligodendroglia. Such analysis will likely reveal toxic 
mechanisms of neuronal cell death in MSA, thereby providing novel targets for MSA therapeutics. 
Hopefully, other diseases in which glial deficits lead to neuronal cell loss will also benefit from 
such advances.  
 
Finally, α-synuclein is not normally expressed in oligodendrocytes of a mouse brain 
(Yazawa et al., 2005) or a human brain (Solano et al., 2000; Miller et al. 2005). Clearly, a 
future advance in MSA research will be determining the cause for ectopic overabundance 
of α-synuclein in GCI-containing oligodendrocytes.  Both in vitro and in vivo MSA 
systems offer complementary approaches to assess the cause of the abnormal expression of 
-synuclein in oligodendrocytes in the disease, and would allow us to act before symptoms 
occur by determining risk factors as well as drug targets.   
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Chapter 6:  CONCLUSION AND SIGNIFICANCE  
 
Two major findings arise from my PhD work and contribute to the understanding of MSA: 
1. High expression levels of -synuclein in oligodendrocytes are sufficient to induce 
formation of GCIs.   
2. -synuclein expression in oligodendrocytes leads to upregulation of the pro-
apoptotic Fas receptor.  This cell culture finding was confirmed in MSA patients, 
providing novel insight to the mechanisms by which -synuclein induces 
cytotoxicity.   
 
These results suggest -synuclein expression in oligodendrocytes may be the primary 
cause of oligodendrocyte dysfunction and death in MSA.  Fas upregulation may contribute 
to the damage of oligodendrocytes in the chronic disease MSA and opens new avenues for 
the development of therapeutic approaches against oligodendroglial pathology.  An 
understanding of the correlation between -synuclein expression and Fas upregulation in 
oligodendroglial -synucleinopathy would offer new targets for therapeutic intervention.  
The models of -synuclein overexpression in oligodendrocyte culture I developed should 
prove useful in clarifying these issues and may allow the development and testing of 
compounds that could prevent oligodendrocyte degeneration. 
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